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ABSTRACT 
 Dengue Fever, known commonly as Break bone fever is the most 
common Arboviral mosquito borne disease in the world. This dengue virus is 
spread by the bite of infected Aedes mosquito, most commonly Ae. aegypti. 
Many countries especially the countries of the Indian subcontinent have 
suffered at the hands of this disease Dengue has a varied and wide spectrum of 
clinical presentations, often with unpredictable clinical evolution and outcome. 
This study is an attempt to derive the clinical profile of Dengue infection from 
the current epidemic that stormed Tirunelveli district. To identify some peculiar 
features that may help in early recognition and appropriate case management. 
The present study is an observational study where we studied the clinical profile 
of 251 serologically proven dengue patients admitted in the Department of 
Medicine, Tirunelveli Medical College from April 2012-March 2013. 
 Out of 251 cases, 149 patients (59.40%) belonged to DCF, DHF in 76 
patients (30.30%), where as 26 patients (10.40%) belonged to more severe 
variety of DSS. Majority of cases 40.20% occurred in young adult <20 years of 
age. The incidence appeared to reduce with advancing age with least number of 
cases seen in the age group >60 years of age. DCF (44.30%) and DSS (42.30%) 
was more common in the younger age group <20 years.DHF (39.50%) was 
more common in age group of 20-29 years where as DSS is not observed in 
patients >60 years in this study. Distribution of dengue in females was slightly 
higher 51.40% when compared to males 48.60%. In this study all patients had 
fever 100%. Followed by headache 61%, Myalgia 54.60%, chills 46.20%, 
abdominal pain 43.40%, vomiting 42.20%.The characteristic feature of dengue 
like bone pain and retro-orbital pain was present in only 3.20% and 32.70% 
respectively. Atypical clinical feature like seizure was present in 1.20%. Most 
common sign observed in this study was conjunctival congestion 23.90%, 
followed by Hepatomegaly 12%, Ascites 10%, Rashes 10%, Pleural effusion 
9.60%, Puffiness of the face and Splenomegaly 8.40%. Most common bleeding 
manifestation encountered was malena 27.50% followed by petechiae 8.40% 
and gum bleeding in 4.80% less frequent was bleeding manifestation 
hemoptysis 0.40%. BP is the most important clinical monitor in a case of 
dengue for identifying onset of complications like shock. Pulse pressure is more 
important than BP in identifying early stage shock. Narrowed pulse pressure (< 
20 mm of Hg) is the most sensitive sign. 
 87 cases showed enzyme abnormalities in 100% cases with LFT 
abnormality which was similar to our study. This could be due to direct injury to 
liver cells by the virus or due to immunological response. Ischemic hepatitis in 
patients especially in shock could be another possible etiology USG was more 
sensitive in picking up Pleural effusion.  
 Out of 251 patients mortality rate was 0.8% Recovery rate was 99.20%. 
The cause of death was intra cerebral bleed/ encephalopathy/seizures / DSS/ 
DIC/Refractory shock in one case. The other case succumbed due to massive 
malena/encephalopathy/DSS/DIC/refractory shock. 
Key Words: Dengue, DHF, DSS. 
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 Dengue Fever, known commonly as Break bone fever is the most 
common Arboviral mosquito borne disease in the world. Many countries 
especially the countries of the Indian subcontinent have suffered at the hands 
of this disease. Epidemiology of Dengue Fever in Indian subcontinent is 
very complex. It has changed over the last few years with regard to the 
strains, affected regions and disease severity.                                                      
 Dengue has a varied and wide spectrum of clinical presentations, 
often with unpredictable clinical evolution and outcome. Most of the patients 
will recover following a self-limiting, less severe clinical course, where as a 
small proportion of patients with dengue infection, progress to severe 
disease, characterized by plasma leakage, with or without hemorrhagic 
manifestations. 
 Intravenous rehydration of the patient is the treatment of choice. By 
this simple intervention, case fatality rate is reduced to less than 1% even in 
severe cases.  
 Clinical profile of dengue fever may vary with each epidemic because 
of the numerous strains available, varied possibilities of co-infections 
according to the geography and also due to the vector density of the 
particular area of outbreak.  
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 This study is an attempt to derive the clinical profile of Dengue 
infection from the current epidemic that stormed Tirunelveli district. An 
effort is also made to identify some peculiar clinical features that may help 
us to identify those seemingly simple cases that worsen without any warning 
signs, so that we may reduce the serious morbidity and mortality associated 
with this disease. 
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Fig: 1 Aedes aegypti (Tiger Mosquito)
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AIM 
 
 
1) To study the clinical profile of serologically proven dengue fever in 
Tirunelveli Medical College hospital. 
 
2)  To identify some peculiar features that may help in early recognition 
and appropriate case management which all together helps in bringing 
out a good clinical outcome.   
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REVIEW OF LITERATURE 
HISTORY: 
 Dengue is one of the most common mosquito-borne arbo viral 
diseases. History of dengue dates back from the period of Jin dynasty. 
Initially it was referred as WATER POISON as it was thought to be spread 
by flying insects. The word DENGUE is derived from the Swahili phrase 
KA-DINGA PEPO which means ―Cramps like seizure‖. Later Benjamin 
Rush called it ―BREAK BONE FEVER ―as it causes severe arthralgia and 
myalgia
1
. 
INCIDENCE: 
 Its incidence has been in increasing trend in the recent years. About 
2.5 billion people reside in dengue endemic countries and its annual 
incidence is estimated to be around fifty million
2
.  
 Dengue has shifted its focus from urban and peri urban areas to rural 
areas
3,4
. And also it is said to exhibit seasonal variations
5
 which is 
determined by the characteristics of the vector, agent and host. 
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DENGUE IN INDIA: 
 The epidemiology of Dengue Fever in Indian subcontinent is very 
complex. It has changed over the last few years with regard to the strains, 
affected regions and disease
6
 severity. 
 Dengue was first reported in India in 1946
7
.Then for the next 18 
years, there was no further epidemic. In 1963 to 1964, an outbreak was 
reported in the Eastern coast of our country, which then spread and reached 
Delhi by 1967
8
. Gradually it involved the entire country. 
 The Kanpur epidemic
9
 in 1967 was due to DV-4 and in 1969
10
 
epidemic, both DV-2 and 4 were isolated. The Vellore epidemic 
11,12
 of 1966 
was reported to be due to DV-3 strain.DV-3 was also reported from 
Calcutta
13
 in 1983, Gwalior In 2003, 2004
14,15
 and at Tirupur, Tamilnadu in 
2010
16
. 
 The outbreaks in Delhi during 1996 reported DV-2 and in 2003 it was 
due to DV-2 and DV-3 strains. At Delhi till 2003
15
 DV-2 was the 
predominant serotype reported, which was then replaced by DV1 strain for 
about a period of three years from 2007 to 2009
17
. Concurrent infection by 
Chikungunya and DV-2 was reported from Vellore
18
 and Delhi
19
. 
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 The emergence of DV-4 which was related to increased severity was 
reported in Andhra Pradesh in 2007
20
 and in Pune 2009 to 2010
21
. 
Phylogenetic analysis revealed that the strains isolated from South India 
were closely related to Gwalior and Delhi isolates.  
Approximate number of Dengue cases and death reported during 2012
22
 
were  
Table: 1 
States, Union Territories that were most affected in 2012 
States, Union Territories No of Cases Deaths 
Tamilnadu 12826 66 
West Bengal 6456 11 
Kerala 4172 15 
Karnataka 3924 21 
Delhi 2093 04 
Puducherry 3506 05 
 
Case fatality rate in India approximately ranges from 3-5% 
23
  
AGENT: 
 Dengue virus is a single-stranded RNA virus. It has four serotypes 
Dengue1,2,3,4. They belong to the Flavivirus genus of family 
―Flaviviridae‖24,25.                                                                                                                                                                              
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 This spherical shaped virus is of 50 nm diameter. It has multiple 
copies of 3 structural proteins, a bilayered membrane derived from host and 
a single copy of single stranded RNA. 
 This RNA is cleaved by host and viral proteases into 3 structural 
proteins: a capsid C, a prM (the precursor of membrane M) and a protein and 
envelope E. It also contains 7 nonstructural proteins. Each serotype has 
many distinct genotypes within. Among them genotypes DEN-2 and DEN-3 
are known to cause serious infections
26,27,28
. Intra host viral diversity 
(QUASISPECIES) is also seen in human hosts. 
 
VECTOR: 
 This dengue virus is spread by the bite of infected Aedes mosquito, 
most commonly Ae. aegypti 
29, 30
. This mosquito is mostly seen in tropical 
and sub tropical countries. Since it cannot withstand lower temperatures, it is 
uncommon above 1000 meters
31
. The immature stages inhabit artificial 
collection of water nearby human dwellings. Dengue epidemics have also 
been occurred due to Aedes polynesiensis, Aedes albopictus and Aedes 
cutellaris complex
32
.
 
The eggs can remain viable for long period even 
without water
33
. 
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HOST: 
 Incubation period of dengue fever is about 4-10 days. The dengue 
virus enters the host through cutaneous route when an infected mosquito is 
sucking its blood meal. Following infection with dengue virus, the patient 
can have varied clinical presentations, although many remain asymptomatic. 
Primary infection with any one of the serotype will result in lifelong 
immunity for that particular serotype
34
.  
 Following primary infection, the infected individuals are protected 
from other serotypes for about 2-3 months but there will be no long-term 
cross-protectivity
35,36
. Monocyte/macrophages play a key role in the 
pathogenesis of DF and then to the origin of DHF and DSS. Infection with a 
heterologous dengue virus may lead to the production of antibodies that are 
non protective. These sub neutralizing levels of antibodies enhances the 
infectivity of virus 
37-40
 . 
 Cross-reactive memory T cells that are rapidly activated during the 
course of secondary infection. This activated T cells proliferate, express 
cytokines and undergo apoptosis in a manner producing plasma leakage 
from capillaries, thereby causing haemoconcentration and abnormalities in 
homeostatic mileau, and thus leading to severe dengue 
41
.  
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  In the course of secondary infection, antibody-dependent 
enhancement (ADE) of infection was proposed as a mechanism in the 
causation of severe dengue
42,43
. This explains the reason why severe dengue 
is regularly found during primary infection in infants born to dengue-
immune mothers. In this model, non-neutralizing cross-reactive antibodies 
that are formed during primary infection, or that are acquired passively at 
birth, bind to the epitopes present on the surface of the heterologous 
infecting virus and this in turn facilitates virus entry into Fc-receptor-bearing 
cells
44,45,46
. 
 The number of infected cells is therefore increased and this results in a 
high viral burden and induction of a profound host immune response that 
includes release of inflammatory mediators, some of which are attributed to 
cause capillary leakage.  
   The clinical outcome of infection in an individual is also said to be 
influenced by the host genetic determinants but this issue is not adequately 
addressed in most of the studies
47,48
. The severity of the disease is also 
influenced by the time interval between the infections and the specific viral 
sequence of the infection. 
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TRANSMISSION OF THE DENGUE VIRUS: 
 The main amplifying hosts of the virus are humans. Dengue virus 
circulating in the blood of infected humans during the acute phase of illness 
is ingested by female Aedes mosquitoes during feeding. The ingested virus 
then infects the mosquito‘s mid-gut and over a period of 8-12 days, systemic 
spread occurs. After this period of extrinsic incubation, the dengue virus can 
be transmitted to other humans during subsequent probing or feeding. 
Environmental conditions, especially ambient temperature influence this 
extrinsic incubation period. 
 Infected mosquito spreads the disease throughout its lifetime; its 
distribution is an important factor in determining the epidemic. Aedes 
mosquitoes bites several times before completing the oogenesis, and thrive 
in close proximity to humans. Being highly anthropophilic, Ae. aegypti is 
one of the most efficient vectors associated with arboviral transmission. 
 Vertical transmission
49 
(transovarial transmission) of dengue virus has 
also been demonstrated in the laboratory but not very often in the field. The 
concept of vertical transmission in the maintenance of the dengue virus is 
also not well understood. Apart from the environmental and climatic 
conditions, the dynamics of viral transmission is also influenced by host-
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pathogen interactions and the immunological factors that are prevalent in a 
particular population
50
. 
Fig: 2                                                     Fig: 3 
                    
Fig: 4 
           
Breeding Source of Aedes Mosquito 
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THROMBOCYTOPENIA IN DENGUE INFECTION:  
Thrombocytopenia occurs in dengue as a result of  
 1. Alterations in megakaryocytopoiesis when human haematopoietic 
cells  are infected with dengue virus, resulting in impaired progenitor cell 
growth thereby causing platelet dysfunction.  
 2. Enhanced destruction of platelets.  
 3. Increased consumption (due to peripheral sequestration) of 
platelets. 
 Hemorrhage can occur as a consequence of the thrombocytopenic 
state and associated platelet dysfunction or it can be due to disseminated 
intravascular coagulation
51,52,53
. 
CLINICAL FEATURES: 
DCF: 
 Incubation period is usually 4-6 days. It is followed by abrupt onset of 
high grade fever (39 to 40 degree) followed by remission for about two days. 
Next comes second febrile phase (SADDLE BACK), chills, headache, retro 
orbital pain, myalgia, arthralgia etc
54
. Rarely sore throat and conjunctival 
suffusion (fig 6) may occur, Constitutional symptoms like Anorexia, nausea, 
disguise, vomiting are common. Transient generalized erythematous 
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Fig: 5 Erythmatous Rashes 
 
 
Fig: 6 Conjunctival Suffusion  
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 rash appears on the trunk which may spread centripetally to face, trunk and 
limbs which at times  resolves with desquamation
55
. (Fig 5) 
 Physical examination may reveal relative bradycardia, hepatomegaly, 
splenomegaly, lymphadenopathy
56
. Monitoring for warning signs like 
petechiae and mucosal membrane bleeding
56, 57 
should be done.  Massive 
haemorrhagic phenomena like vaginal bleeding, gastrointestinal bleeding, 
epistaxis and other bleeding may occur during this phase
57
. The earliest 
alarm is a progressive decrease in white blood cells
56
. Clinically, it may be 
very difficult to distinguish dengue from other febrile diseases in the early 
phase. A positive tourniquet test during this phase increases the probability 
of diagnosis of dengue
56,58
. 
DHF: 
 Most common in young adults around 12 years of age. This is 
characterized by fever, major /minor bleeding manifestation and evidence of 
plasma leakage like pleural effusion and ascites supported by 
thrombocytopenia and hemoconcentration
59,60
. Development of DHF with 
progressively decreasing platelet count and rising haematocrit is an alarm for 
impending shock. 
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Fig :7 Gum Bleeding                              Fig 8 Palatal Petechiae  
        
 
 
 
Fig: 9 Lower Limb Petechiae             Fig: 10 Conjunctival Hemorrhage 
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DSS: 
 DSS is defined as DHF along with signs of circulatory failure like 
narrow pulse pressure, hypotension and frank shock with warning signs of 
sustained abdominal pain, persistent vomiting, restlessness, lethargy, 
hypothermia and sweating. Physical signs may include blotchy skin, 
cyanosis, tachypnoea, hepatomegaly, pleural effusion, edema and oliguria
61
. 
  In the initial stage of shock there will be a compensatory mechanism 
which maintains the systolic pressure and may misguide the clinician. There 
will be peripheral vasoconstriction, tachycardia, cold extremities and narrow 
pulse pressure because of high vascular resistance. This is followed by stage 
of decompensatory shock which is characterized by hypotension, hypoxia 
and finally multi-organ failure, acidosis and DIC. Patient may recover after 
volume correction but there is chance of recurrence due to excessive 
capillary permeability. During the recovery phases, excessive fluid therapy 
may subject to pulmonary edema or congestive heart failure
62,63
. 
RARE PRESENTATION: 
 Rare presentations of dengue like Acute liverfailure
64
, 
encephalopathy
65,66, Myocarditis67,68,69, ARDS and Renal failure70 should 
also be thought of.
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  Reducing dengue mortality requires early recognition of the disease, 
simple but effective triage principles and timely decisions regarding the 
management, which may all helps in identifying those people at risk of 
developing severe disease.  
 In a study conducted at a teaching hospital in North India
71
 regarding 
clinical profile of dengue fever.  It was shown that out of 356 patients with 
suspected dengue fever 138 patients with serologically confirmed dengue 
was included in the study. 
 Of them 58% patients were males and 42% were females. 70% 
patients had classical dengue fever; where as 30% had dengue hemorrhagic 
fever. The most common symptoms observed in the study were headache 
76%, abdominal pain in 63%, vomiting in 58%, where as rash and cutaneous 
hypersensitivity were present in 26% and 16% respectively. 
  Hemorrhagic manifestations were present in 40% patients. Atypical 
manifestations were also recorded in 14% of patients who had neurological 
involvement
72
 and liver enzymes elevation, were also noted in dengue 
infection 
73,74
 . In this present study, AST levels were equal to or greater than 
those of ALT levels in all of dengue infected patients, a finding that has also 
been reported earlier
75
 4% of them had acute hepatic failure
76
. Overall 
 
 
22 
 
mortality was recorded to be 6% and death was observed due to multi-organ 
failure.  
 In another prospective study conducted in 100 confirmed cases of 
dengue fever in North Karnataka
77
 from May 2012 to April 2013, it was 
observed  that majority were males 54%,  and the most common age group 
affected was between16-40 years.  
 The most common presentation was fever which was present in all the 
100 cases, followed by headache in 90%, myalgia in 81%, vomiting in 56% 
and abdominal pain in 48%. 22% of them had dengue hemorrhagic fever and 
among the hemorrhagic manifestations observed, the most common was 
petechiae 21%. Dengue shock syndrome (DSS) was present in16%. Pleural 
effusion was found in 70% of patients and right sided pleural effusion was 
found in 52% of patients. USG abdomen had revealed ascites in 54% of 
patients. 
  The most atypical clinical feature noticed was encephalitis and very 
rarely GBS
78,79
. The other unusual features observed were observed were 
hepatic dysfunction (34%), renal failure (26%), multi organ dysfunction 
(18%), encephalopathy (13%), ARDS (12%), and finally 11% death were 
reported.  
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  Hepatic Dysfunction was studied in 70 serologically proven dengue 
patients
80
. SGOT levels were higher than SGPT levels in them. 
Hepatosplenomegaly and ascites were also present.  
 Usually involvement of liver in dengue has been reported frequently 
in children.
81,82
  But  in adults there are only few studies supporting this 
evidence 
83-86.
 In the present study, it was noted that SGOT levels were 
elevated than that of SGPT levels. The reversal of this will be seen in 
malaria and enteric fever
87
. According to Srivenu Itha et al, the study 
conducted had showed no significant elevation of liver enzymes in dengue
88
. 
 SGOT- elevated in 100% 
 SGPT level- elevated in 91% 
 SGOT level> twice the upper limit of normal-85% 
 SGPT levels> twice the upper limit of normal-48%.  
 Hepatomegaly-50% 
 Splenomegaly-21%89  
 Ascites-60% 90 
 Pleural effusion- 15% 
 Leucopenia- 10% 
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 Though the mechanisms involved in derangement of liver enzymes in 
dengue was not very clear it was believed that it may be due to direct injury 
to liver cells or due to an immunological response. None of their patients 
had DSS. Therefore shock as a major cause of liver injury was ruled out. 
 Dengue haemorrhagic fever among adults – an observational study 
was conducted in Chennai, here 128 cases who were fullfilled the diagnostic 
criteria for DHF according to WHO case definitions were included
91
.  
 In that study, males and females were affected in equal proportion in 
the ratio of 1:1. The average duration of fever was 4 days with the range of 
2-6 days. The most common symptom was fever, present in 100%, followed 
by myalgia in 68%, gingival bleeding in 63%, headache in 57%, fatigability 
in 42% and arthralgia in 20%.  
 Among the bleeding manifestations, 46% had petechiae or purpura, 
12% had sub-conjuctival bleed, 11% had ecchymosis and 10% had rashes.  
9% of them had malena and 8 of them had menorrhagia, 22% of them had 
hepatomegaly and 5% had splenomegaly. Also, 37% showed hypotension. 
Leucopenia was present in 57% patients. 
  Thrombocytopenia was present in 18% patients and hepatitis was 
noted in 27.3% patients. Of them, 18.6% of patients with elevated 
transaminase values (> 1000 IU/l) were suspected to have ischemic hepatitis 
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since they were in shock. When USG is done 62.5% were diagnosed to have 
pleural effusion whereas only 27% people showed pleural effusion in chest 
X-ray, 14% had ultrasound evidence of gall bladder wall thickening and 
Dengue IgM antibodies was positive  in 46% cases. 
NS1 ANTIGEN: 
  NS1( non-structural protein 1) Antigen testing also known as Platelia 
Dengue NS1 Ag assay, is a test for dengue that allows rapid detection of 
dengue infection on the first day of fever, even before the appearance of 
antibodies. Recently, NS1 antigen has gained interest as a new and early 
biomarker for the early diagnosis of DENV infection. Dengue NS1 antigen 
is a highly conserved glycoprotein, produced both in membrane-associated 
and secretory forms 
92
. 
MAC-ELISA:  
 IgM antibody capture ELISA is especially useful in the diagnosis of 
recent infection. These are relatively specific for dengue but do not 
distinguish between various serotypes. Rising titer of IgM antibodies is 
much more specific.  
 Regarding IgG ELISA, this can be used for the diagnosis of a 
previous dengue illness. Those patients with first degree dengue infection 
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will have negative IgG test in the acute phase of illness and then become 
positive for IgG antibodies in the convalescent phase. Whereas patients with 
second degree dengue infection show positive IgG test in the acute phase 
with a fourfold increase in IgG titer in the convalescent phase.
93   
RT-PCR: 
 Reverse transcriptase PCR is a specific and sensitive test to detect 
viral RNA. Hybridisation probes helps to identify viral nucleic acid
94. 
BLOOD CHEMISTRY:  
 Platelet count and haematocrit should be monitored 6
th
 hourly. 
Thrombocytopenia and hemoconcentration are constantly observed in DHF. 
Platelet count usually drops below one lakh between the third and eighth day 
of illness. 20% increase in haematocrit from the baseline value is consistent 
with plasma leakage when there is drop in the haematocrit, it is suggestive of 
bleeding.
95
  
 Leucopenia with reduction in the number of neutrophils and relative 
lymphocytosis may also be observed
96
. 
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  Other investigations like Liver function tests, renal function tests, 
blood sugar levels, serum electrolytes, bicarbonate or lactate, cardiac 
enzymes, ECG and urine specific gravity can be done as indicated. 
Management decisions 
 Depending on the clinical manifestations, patients may grouped into 
three categories
97
 as follows, 
1. Group A-includes those who can be sent home  
2. Group B- those who require hospital management 
3. Group C- those who need emergency treatment and urgent referral. 
Group A includes patients who can be managed at home. In the absence of 
signs of dehydration or bleeding, they should be reviewed every day for 
disease progression, until they are out of the danger. Patients should be alert. 
Group B includes those patients who need in-hospital management. 
Admission criteria 
 Presence of warning signs related to hypotension, dehydration, 
profuse sweating, cold extremities, bleeding manifestation or co-morbid 
condition warrants admission. In these patients, careful and repeated 
estimation of volume status and fluid replacement are the cornerstone of 
management.
23
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  If the patient has dengue with warning signs, the action plan should 
be as follows:  
 Baseline haematocrit should be observed before fluid therapy. 
Isotonic solutions like 0.9% saline or RL or Hartmann‘s solution should be 
preferred.  
   5-7ml/kg/hr for1-2hours, 
                                                   Assess if vitals are stable  
                                3-5 ml/kg/hr for 2-4 hours,  
     Assess if vitals are stable    
             2-3 ml/kg/hr or less depending upon clinical response. 
 Following fluid therapy, reassess the clinical status and repeat the 
total blood count and haematocrit. Here, it is very important to change the 
rate of fluid infusion frequently, with the aim to maintain good perfusion and 
adequate urine output of about 0.5 ml/kg/hr
23
.  
Group C:                                                                                                                                         
 Patients who require emergency treatment and urgent referral are 
those who have evidence of severe plasma leakage, leading to dengue shock 
and fluid accumulation with complication like, profuse hemorrhages, 
multiple organ failure, and respiratory distress. 
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  In cases of hypotensive shock, colloid solutions are preferred. 
Continuous replacement of further plasma losses is essential to maintain 
effective circulation for 24-48 hours. Blood grouping and cross matching 
should be done meanwhile for all patients in shock. Blood transfusion is 
carried out only in cases with suspected/severe bleeding. 
Treatment of compensated shock: 
 For those patients with compensated shock,   
Isotonic fluid should be administered                       
            5–10ml/kg/hr  
     Reassess, if vitals stable   
     5-7ml/kg/hr for 1-2 hours, 
 
                                3-5ml/kg/hr for 2-4hours, 
                                                      
   2-3ml/kg/hr maintenance 
  Further infusion depends on hemodynamic status, and can be 
maintained for up to 24-48 hours. 
 If shock persists or if the vitals are unstable, check the haematocrit 
after the first bolus. If the haematocrit is persistently high (>50%), repeat a 
second bolus of crystalloids at 10-20 ml/kg/hr for one hour. After the second 
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bolus, if there is improvement, reduce the infusion, and then continue to 
reduce as above. The goals of fluid resuscitation are to improve central and 
peripheral circulation and to enhance end-organ perfusion. 
 If haematocrit decreases with respect to the initial reference 
haematocrit (<40% in children and females, <45% in males), then there is 
internal bleeding and so transfuse blood as soon as possible. Patients with 
hypotensive shock should be managed vigorously 
 Treatment for patients in decompensated shock: 
 Initiate intravenous fluid resuscitation with crystalloid or colloid 
solution at the rate of 
                     20 ml/kg as a bolus, over 15 minutes. 
                      Patient improves give crystalloid/colloid  
                      10 ml/kg/hr over one hour. 
                                                  If haematocrit was high, switch to colloids  
                      10–20ml/kg as a second bolus over 30-60minutes                
 Then to follow the protocol of compensated shock 
99-103
, if the vitals 
were stable. 
 If vital signs are still unstable, review the haematocrit, before the 
second bolus. If the haematocrit has reduced, suspect internal bleeding and 
consider blood transfusion. 
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 The higher the fluid infusion rate, more frequently the patient should 
be monitored and reviewed, so as to avoid fluid overload. 
Treatment of hemorrhagic complications: 
 Mucosal bleeding should be considered as minor, if the patient 
remains stable with fluid resuscitation/replacement and there is no need for 
any blood transfusion. Bleeding usually improves rapidly during the 
recovery phase. Intramuscular injections should be avoided for fear of 
formation of hematoma. In otherwise haemodynamically stable patients, 
prophylactic platelet transfusions for severe thrombocytopenia have not been 
shown to be effective and not necessary.  
Severe bleeding is recognized by: 
 Persistent / overt bleeding in the presence of unstable haemodynamic 
status, irrespective of the haematocrit level.  
 A decrease in haematocrit after fluid resuscitation together with 
unstable hemodynamic status. 
 Refractory shock not responding to consecutive fluid resuscitation of 
40-60 ml/kg. 
 Hypotensive shock with low/normal haematocrit prior fluid 
resuscitation 
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 Persistent/worsening metabolic acidosis ± a well-maintained systolic 
blood pressure, particularly in those with severe abdominal tenderness 
and distension. 
 Haematocrit of <30% as a trigger for blood transfusion, as 
recommended by the Surviving Sepsis Campaign Guideline 
104
 ,is 
inapplicable to severe dengue, as in dengue, bleeding usually occurs 
after a period of prolonged shock, preceded by plasma leakage. 
 
The action plan for the treatment of hemorrhagic complications is as 
follows: 
 
 Infuse 5-10ml/kg of fresh-packed red cells or 10-20 ml/kg of fresh 
whole blood at a suitable rate and observe the clinical response. It is 
important to give fresh whole blood or fresh red cells as Oxygen 
delivery at tissue level is optimal when levels of 2,3 di-
phosphoglycerate  are high and stored blood loses 2,3 DPG, which 
impede the oxygen-releasing capacity of hemoglobin, leading to 
functional tissue hypoxia. A positive clinical response includes 
improving haemodynamic status and acid-base balance. 
 Repeat blood transfusion if there is further blood loss or no 
appropriate rise in haematocrit following the initial blood 
transfusion. There is no proper evidence to support the practice of 
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transfusing platelet concentrates and fresh-frozen plasma in cases of 
severe bleeding. Those can be given when massive bleeding cannot 
be managed with just fresh whole blood/fresh-packed cells alone. 
However, it may exacerbate the fluid overload. 
 The management of fluid overload varies with respect to the phase of 
the disease.  
Complications of dengue: 
 
• Both hyperglycemia and hypoglycemia are prone to occur, even in the 
absence of diabetes mellitus or hypoglycemic agents.  
• Electrolyte and acid-base imbalances are also common complications 
in severe dengue and are probably due to gastrointestinal losses 
through vomiting and diarrhoea or due to the use of hypotonic 
solutions for resuscitation and dehydration correction.  
• Hyponatraemia, hypo/hyperkalaemia, serum calcium imbalances and 
metabolic acidosis can also occur. 
• Co-infections and nosocomial infections are not uncommon. 
 
Differential diagnosis of dengue fever:  
 
 Flu-like syndromes Influenza, measles, Leptospirosis, infectious 
mononucleosis, HIV, seroconversion illness, Illnesses with a rash Rubella,  
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scarlet fever, meningococcal infection, drug reactions, diarrhoeal diseases, 
Rotavirus or other enteric infections, Illnesses with neurological 
manifestations, Meningo/encephalitis, Febrile seizures. 
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METHODOLOGY 
 
Settings:    Department of Medicine, Tirunelveli   
     Medical College and Hospital. 
Collaborative Department:  Department of Biochemistry,  
     Department of Microbiology, 
     Department of Pathology, 
     Department of Radiology. 
Study Design:     Hospital based cross sectional Observational          
     Study. 
Period of Study:    April 2012 to March 2013 
Sample size:    251 cases 
Ethical committee approval: The present study was approved by the  
     Institutional Ethical committee. 
Inclusion Criteria: 
 Fever with thrombocytopenia with Dengue antigen(NS1) or 
antibody(IgG or IgM) positivity 
 Adults with age more than 13 years. 
Exclusion Criteria: 
 Fever with thrombocytopenia due to other causes 
Materials: 
 Total of 251 serologically proven dengue cases, who satisfied the 
inclusion and exclusion criteria were taken up for the study.  
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Methods: 
Complete history, signs, symptoms and laboratory data were recorded as per 
the Performa. 
Investigations: 
The following investigations were performed in all the patients. 
Blood: 
TC, Platelet Count, Haematocrit, LFT, RFT, Electrolytes 
Radiology  
X-ray chest, 
USG Abdomen 
Statistical analysis: 
The data was entered in the Microsoft Excel, spread sheet and analyzed 
statistically using standard statistical software, SPSS for windows. Chi 
Square test used for categorical variables. Significance was considered if the 
‗p‘ value was below 0.05. 
Cases were defined as per WHO guidelines:- 
Dengue Classical Fever (DCF): 
An acute febrile illness with two or more of the following 
 Headache  
 Retro orbital pain 
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 Myalgia and Arthralgia 
 Skin rash 
 Hemorrhagic manifestation 
 Nausea, vomiting and 
 Supportive serology. 
Dengue Hemorrhagic fever (DHF): (all 4 criteria required) 
 Fever or history of fever lasting for 2-7 days 
 Bleeding tendencies indicated by either a positive tourniquet test  
Petechiae, ecchymoses and purpura 
Bleeding per mucosa, Haematemesis, malena etc. 
 Thrombocytopenia less than one lakh 
 Plasma leakage evidenced by  
Rise in haematocrit more than 20% or fall in haematocrit more than 
20% after iv fluids 
Pleural effusion, ascites, hypoalbuminemia 
Dengue Shock Syndrome (DSS): 
DSS require all DHF criteria in addition to circulatory failure manifested by   
 Rapid and weak pulse 
 Narrow pulse pressure < 20mm of Hg 
 Hypotension 
 Cold dry skin, restlessness.  
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Normal Values: 
Hemoglobin 
Adult male  13.3 - 16.2 gm/dl 
Adult female  12 - 15.8 gm/dl 
Leucopenia    4000 cells /dl 
Haematocrit  
Adult Male   38.8 - 46.4 
Adult Female          35.4 - 44.4 
LFT 
Bilirubin 
Total    0.3 - 1.3mg/dl 
Direct  0.1- 0.4 mg/dl 
Indirect   0.2 – 0.9mg/dl 
ALT     7-41 U/L 
AST     12 – 38 U/L 
RFT 
Serum Urea  15 - 40 mg/dl 
Reference values are from  
(Harrison laboratory values of clinical importance). 
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RESULTS 
 The present study is an observational study where we studied the 
clinical profile of 251 serologically proven dengue patients admitted in the 
Department of Medicine, Tirunelveli Medical College from April 2012 -
March 2013. 
  The study had revealed much observation that concurred with 
traditional teaching about dengue, there were other findings that were 
peculiar to this epidemic. The observations are as follows, 
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Clinical classification of cases 
Table 2: Clinical Spectrum of Cases 
Clinical spectrum 
of cases 
No. of 
cases 
Percent 
DSS 26 10.4 
DHF 76 30.3 
DCF 149 59.4 
Total 251 100 
 
 
Fig: 11 Clinical Spectrum Of Cases 
 
 Out of 251 cases, 149 patients (59.40%) belonged to DCF, DHF in 76 
patients (30.30%), where as 26 patients (10.40%) belonged to more severe 
variety of DSS. The details are given in the above table. 
 
 
DSS,  
10.40% 
DHF,  
30.30% 
DCF,  
59.40% 
 
 
43 
 
Table: 3 Distribution of Age 
Age Frequency Percent 
< 20 yrs 101 40.2 
20 - 29 77 30.7 
30 - 39 27 10.8 
40 - 49 22 8.8 
50 - 59 19 7.6 
> 60 yrs 5 2.0 
Total 251 100 
 
 
Fig 12 Distribution of Age 
 
  
 Majority of cases 40.20% occurred in young adult <20 years of age. 
The incidence appeared to reduce with advancing age with least number of 
cases seen in the age group >60 years of age.  
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Table: 4 Associations between Dengue type and age 
 
Dengue Clinical Type 
Age (Code) DSS DHF DCF 
  < 20 yrs 42.30% 31.60% 44.30% 
 
20 - 29 26.90% 39.50% 26.80% 
 
30 - 39 3.80% 13.20% 10.70% 
 
40 - 49 15.40% 5.30% 9.40% 
 
50 - 59 11.50% 6.60% 7.40% 
 
> 60 yrs - 3.90% 1.30% 
 
Fig:13 Associations between Dengue type and age 
 
 DCF (44.30%) and DSS (42.30%) was more common in the younger 
age group <20 years.DHF (39.50%) was more common in age group of 20-
29 years where as DSS is not observed in patients >60 years in this study. 
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Table: 5 Analysis in respect to gender distribution 
Gender Frequency Percent 
Male 122 48.6 
Female 129 51.4 
Total 251 100 
 
 
 
  
 Distribution of dengue in females was slightly higher 51.40% when 
compared to males 48.60%. 
 
 
 
 
Male 
48.60% 
Female 
51.40% 
Fig :14 Gender Distribution 
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Table: 6 Analysis of clinical spectrum with respect to gender 
 
 
  
 
Fig:15 Associations between Dengue type and Gender 
 
 
 DSS was more common in females 65.40%, when compared to males 
34.60% where as DHF in men53.90% when compared to women 46.10%. 
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Gender DSS DHF DCF 
  Male 34.60% 53.90% 48.30% 
 
Female 65.40% 46.10% 51.70% 
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Table :7 Duration of hospital stay 
Duration of Hospital Stay Frequency Percent 
Upto 1 Week 165 65.7 
7 - 14 Days 86 34.3 
Total 251 100 
 
 The average duration of hospital stay of patients in this study was less 
than 1 week. 
 
Table:8  Analysis of symptoms: 
Symptoms Frequency Percent 
Fever 251 100 
Chills 116 46.2 
Headache 153 61.0 
Retro-orbital Pain 82 32.7 
Arthralgia 97 38.6 
Bone Pain 8 3.2 
Muscle Pain 137 54.6 
Nausea 37 14.7 
Vomiting 106 42.2 
Soar Throat 38 15.1 
Seizures 3 1.2 
Abdominal Pain 109 43.4 
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Fig :16  Analysis of  Symptoms 
 
  In this study all patients had fever 100%. Followed by headache 
61%, Myalgia 54.60%, chills 46.20%, abdominal pain 43.40%, vomiting 
42.20%.The characteristic feature of dengue like bone pain and retro-orbital 
pain was present in only 3.20% and 32.70% respectively. Atypical clinical 
feature like seizure was present in1.20% 
 
0% 20% 40% 60% 80% 100% 120%
Fever
Chills
Headache
Retro-orbital Pain
Arthralgia
Bone Pain
Muscle Pain
Nausea
Vomiting
Soar Throat
Seizures
Abdominal Pain
 
 
49 
 
Table:9 Association between Dengue type and Bone Pain 
Bone Pain 
Dengue Type 
Total 
DSS DHF DCF 
Yes 
3 1 4 8 
11.50% 1.30% 2.70% 3.20% 
No 
23 75 145 243 
88.50% 98.70% 97.30% 96.80% 
Total 26 76 149 251 
Chi Square: 6.861;  P < 0.05 
 
Fig 18 Association between Dengue type and Bone Pain 
 
 Even though the bone pain was present in 3.20% it has got statistically 
significant correlation with Dengue classical fever. 
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Table: 10 Analysis of clinical signs 
Signs Frequency Percent 
Icterus 16 6.4 
Pallor 13 5.2 
Conjunctival Congestion 60 23.9 
Hepatomegaly 30 12 
Splenomegaly 21 8.4 
Myocarditis 4 1.6 
Pleural Effusion 24 9.6 
Ascites 25 10.0 
Encephalopathy 4 1.6 
Rashes 25 10.0 
Exfoliative Dermatitis 1 0.4 
Diarrhoea 16 6.4 
Neck Stiffness 1 0.4 
Puffiness of Face 21 8.4 
Breathlessness 1 0.4 
Pneumonia 4 1.6 
Loss of Appetite 1 0.4 
Pelvic Abscess 1 0.4 
Herpes Labialis 1 0.4 
 
 
 Most common sign observed in this study was conjunctival 
congestion 23.90%, followed by Hepatomegaly 12%, Ascites 10%, Rashes 
10%, Pleural effusion 9.60%, Puffiness of the face & Splenomegaly 8.40% 
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Table: 11 Analysis of bleeding manifestation 
Bleeding Frequency Percent 
Gum Bleeding 12 4.8 
Epistaxis 9 3.6 
Petechiae 21 8.4 
Hemetemesis 5 2.0 
Melena 69 27.5 
Hematuria 4 1.6 
Bleeding PR 2 0.8 
Bleeding PV 9 3.6 
   Hemoptysis 1 0.4 
Sub conjunctival hemorrhage 14 5.6 
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Fig: 19 Bleeding manifestation 
 
 
 Most common bleeding manifestation encountered was malena 
27.50% followed by petechiae 8.40% and gum bleeding in 4.80% less 
frequent was bleeding manifestation   hemoptysis 0.40% 
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Table: 12 Associations between Dengue type and Bleeding 
Melena 
Dengue Type 
Total 
DSS DHF DCF 
Yes 
5 28 36 69 
19.20% 36.80% 24.20% 27.50% 
No 
21 48 113 182 
80.80% 63.20% 75.80% 72.50% 
Total 26 76 149 251 
Chi Square: 5.987;  P < 0.05 
   
Malena has got statistically significant association with DHF  
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Table: 13 Analysis of blood pressure in dengue 
Blood Pressure Frequency Percent 
Normal 192 76.5 
Low 54 21.5 
High 5 2.0 
Total 251 100 
 
 
Fig: 20 Analysis of blood pressure in dengue 
 
 
 Blood pressure was normal in 76.50%, eventhough 21.50% of patient 
presented with hypotension, DSS had occurred in 10.40% 
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Fig.9. Blood Pressure 
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Table: 14 Analysis of blood count 
CBC Frequency Percent 
Leucopenia 83 33.1 
Thrombocytopenia 167 66.5 
HCT Increased 73 29.1 
HCT Decreased 58 23.1 
 
 
Fig: 21 Analysis of blood count 
 
 CBC, thrombocytopenia was seen in 66.50%, leucopenia in 33.10% 
haematocrit increased and decreased in 29.10% and 23.10% respectively. 
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Table: 15 Associations between Dengue types and haematocrit 
Haematocrit 
Dengue Type 
Total 
DSS DHF DCF 
Normal 
4 28 88 120 
15.40% 36.80% 59.10% 47.80% 
Increased 
10 20 43 73 
38.50% 26.30% 28.90% 29.10% 
Decreased 
12 28 18 58 
46.20% 36.80% 12.10% 23.10% 
Total 26 76 149 251 
Chi Square: 32.585;  P < 0.001 
 
 
Fig : 22 Associations between Dengue types and haematocrit 
 
Increased haematocrit has got statistical correlation with DSS 
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Table: 16 Analysis of Elevation of Bilirubin 
LFT: Bilirubin Frequency Percent 
Elevated 27 10.7 
Normal 224 89.3 
Total 251 100 
    
 
Fig: 23 Analysis of Elevation of Bilirubin 
 
 
 Serum bilirubin was elevated in 10.70%, where as it was normal in 
89.30%. 
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Table: 17 Analyses of Liver Enzymes 
LFT: Liver Enzymes Frequency Percent 
Elevated SGOT, SGPT, Alk. 
Phosphatae 
41 47.1 
SGOT > SGPT 32 36.8 
SGPT = SGOT 5 5.7 
SGPT > SGOT 7 8.0 
SGOT Only 2 2.3 
Total 87 100 
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Fig 24Analysis of Liver Enzymes 
 
 In LFT, All the three enzymes ALT,AST and ALP were elevated in 
47.10%.SGOT more than SGPT in 36.80%;SGPT more than SGOT;  both 
AST and ALP were almost equally elevated in 5.70%.where as  SGOT only 
in 2.30%. 
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Table: 18 Association of Dengue type and Liver Enzymes 
Liver Enzymes 
Dengue Type 
Total 
DSS DHF DCF 
Elevated SGOT, 
SGPT, Alk. 
Phosphatase 
4 13 24 41 
57.10% 56.50% 42.10% 47.10% 
SGOT > SGPT 
2 10 20 32 
28.60% 43.50% 35.10% 36.80% 
SGPT = SGOT 
1 
 
4 5 
14.30% 
 
7.00% 5.70% 
SGPT > SGOT 
    7 7 
    12.30% 8.00% 
SGOT Only   
2 2 
  
3.50% 2.30% 
Total 7 23 57 87 
Chi Square: 8.445;  P > 0.05 
 
Fig:25 Association of Dengue type and Liver Enzymes 
  
The elevation of liver enzymes has no statistical correlation with any 
particular type of dengue. 
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                          Table: 19 Analysis of  Renal function test 
 
 
Frequency Percent 
Normal 245 97.6 
Compromised 6 2.4 
Total 251 100 
 
 
Fig: 26 Analyses of Renal Function Test 
 
 Renal function test was normal in 97.60%, elevated in 2.40% but it 
has no statistically correlation. 
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Table: 20 Analysis of   ECG 
ECG Frequency Percent 
Sinus Bradycardia 29 11.6 
Sinus Tachycardia 84 33.4 
Brady with I degree AV 
Block 
5 2.0 
Brady with II degree AV 
Block 
2 0.8 
LVH 1 0.4 
T Wave Inversion V1 to V4 1 0.4 
Normal 129 51.4 
Total 251 100 
 
Fig: 27 Analyses of ECG 
 
 ECG was normal in 51.40%. Most frequent ECG sign was sinus 
Tachycardia 33.40%, where as sinus bradycardia in 11.60%, First degrees 
AV block in 2.0%, Second degrees AV block 0.80%. 
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Table: 21 Analysis of USG 
USG Frequency Percent 
Normal 104 41.4 
Hepatomegaly 39 15.5 
Splenomegaly 38 15.1 
GB Wall Edema 60 23.9 
Pleural Effusion 42 16.7 
Ascites 48 19.2 
Others 13 5.2 
 
Fig: 28 Analyses of USG Abdomen 
 
  USG Abdomen was normal in 104 patients. GB wall edema 
was present in 23.90%, Ascites was present in 19.20%, and Pleural effusion 
was seen in 16.70%, Hepatomegaly15.50% and Splenomegaly 15.10%. 
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Table: 22 Analyses of USG Pleural effusion 
USG: Pleural Effusion Frequency Percent 
Right Only 14 33.3 
Bilateral 28 66.7 
Total 42 100 
 
Fig: 29 Analyses of USG Pleural Effusion 
 
 In USG Right side Pleural Effusion was seen in 33.30% where as 
bilateral effusion was more common and it was present in 66.70%. 
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Table: 24 Analysis of Chest X-Ray PA View 
Chest X Ray P/A Frequency Percent 
Normal 230 91.6 
Right Pleural Effusion 13 5.2 
Bilateral Pleural Effusion 6 2.4 
Cardiomegaly 1 0.4 
Right Lower Lobe 
Consolidation 
1 0.4 
Total 251 100 
    
Fig: 31 Analyses of Chest X-Ray 
 
  X-ray chest P/A view was normal in 91.60%, here right sided pleural 
was more common 5.20% when compared with bilateral pleural effusion 
2.40%. 
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Table: 25 Analyses of CT Brain 
CT Brain Frequency Percent 
Normal 2 50 
Minimal White Matter Hypo 
density 
1 25 
Intracerebral Bleed 1 25 
Total 4 100 
 
 CT brain was taken for 4 patients presented with encephalopathy. It 
was normal in 2 patients, 1 patient with Seizure had Intracerebral bleed. 
 
Table: 26 Analyses of Blood Transfusion 
Blood Transfusion Frequency Percent 
No Transfusion 161 64.1 
Whole Blood 64 25.5 
Platelet 7 2.8 
Whole Blood + Platelet 15 6.0 
Whole Blood + Platelet + 
FFP 
4 1.6 
Total 251 100 
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Fig: 32 Analysis of Blood Transfusion 
 
 Blood transfusion was not needed for 161 patients. 64 (25.50%) was 
transfused with whole blood, only platelet in 7 patients, whole blood along 
with platelet in 6.0%.whole blood along with platelet and FFP in 1.60%. 
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Table: 23 Analysis of Serology 
Serology Frequency Percent 
NS 1 155 61.8 
IgM 112 44.6 
IgG 4 1.6 
 
 
Fig: 30 Analyses of Serology 
 
 
In serology NSI antigen was positive in 61.80%, IgM in 44.60%, IgG 
in 1.60%. 
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Table: 27 Analyses of Out come 
Outcome Frequency Percent 
Recovered  249 99.2 
Dead 2 0.8 
Total 251 100 
 
 
Fig: 33 Analyses of Out Come 
 
  
Regarding the Outcome, patient‘s recovery rate achieved was 99.20%. 
We lost 2 cases (0.80%) among the 251 cases studied.  
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Table: 28 Associations between Dengue type and Outcome 
Outcome 
Dengue Type 
Total 
DSS DHF DCF 
Recovered 
24 76 149 249 
92.30% 100.00% 100.00% 99.20% 
Dead 
2 
  
2 
7.70% 
  
0.80% 
Total 26 76 149 251 
Chi Square: 17.447;  P < 0.01 
 
 
Fig: 34 Associations between Dengue type and Outcome 
 
 
The death has got statistical correlation with DSS. 
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DISCUSSION 
 This study describes the clinical profile of serologically proven 
dengue cases in adults aged more than 13 years admitted in our hospital 
during the current Dengue epidemic of 2012. 
 A total of 251 cases admitted between April 2012 – March 2013 were 
studied by analyzing the symptoms, signs, hematological and laboratory 
findings, and outcome. 
 The findings are discussed in detail with reference to other studies 
conducted in clinical profile of dengue in various parts of the country. Also 
an attempt is made to find out the significance of various parameters, in 
order to help us diagnose promptly and treat effectively the cases thereby 
reducing morbidity and mortality. 
Clinical spectrum of Cases: 
 The cases studied were classified according to the WHO Diagnostic 
criteria for Dengue published in 2009. 
 Of the total 251 cases studied, 149 cases (59.40%) were diagnosed to 
have DCF, 76 cases (30.30%) were diagnosed with DHF. More severe form 
of dengue DSS constituted 26 cases which was 10.4% of the cases studied. 
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 This clinical distribution of cases as DCF, DHF and DSS in our study 
followed similar pattern that was observed in other studies conducted in 
Uttar Pradesh in 2010 (RituKaroli et al) and Karnataka during the recent 
epidemic of May 2012 – April 2013(Dr Mohan  SDMCMS). In these 
studies, DCF constituted around 70% of cases and DHF and DSS constituted 
the rest. 
 Average hospital stay calculated was, 1 week (65.70%) depending on 
the severity ranged from 1 - 15 days.  
Age Distribution 
 Age group of the cases ranged from 13 – 65 years. Majority of cases 
in this study were young adults belonging to the age group of 20 – 39 years 
of age. Whereas it was less common among age group > 60 years .Incidence 
of dengue showed a decreasing trend with increasing age. The study 
revealed that younger age group was more susceptible to dengue infection in 
our population.  
 DCF showed a highest incidence among cases < 20 years of age 
(44.30%) whereas DHF was common in 20 -29 years age group(39.50%),  
which was slightly more than in cases < 20 years (31.60%). 
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 Incidence of DSS was high among cases < 20 years of age whereas no 
cases with DSS belonged to age group > 60 years.  
 According to WHO, DSS was more prone in children and young 
adults because the compensatory mechanism for capillary leakage was weak 
when compared to adults. 
Gender Distribution 
 51.40% of the cases were females and males constituted 48.60%. 
There was no statistical significance for this finding. DSS was more 
common among females (65.40%) when compared to males (34.60%). 
Similar observation was made by WHO, this might be due to difference in 
genetic background and immune response among males and females. 
Analysis of presenting symptoms 
 Presenting symptoms were analyzed and categorized into common 
presentation and atypical presentation. 
The following were the observations: 
1. Fever: 251 cases (100%) had fever at the time of presentation which was 
similar to the studies conducted in Chennai and North Karnataka. Traditional 
teaching of Saddle back fever in dengue was not observed during our 
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epidemic. Most of the cases had high grade intermittent fever. Fever was 
associated with chills and rigor in 46.20% of cases. A particular periodicity 
was not observed.  
2. Headache and Retro-orbital pain: Headache was the second most 
common symptom (61.0%) similar to the study from North Karnataka 
(2013) and Uttar Pradesh (2010).   
Retro orbital pain was observed in 32.70% of cases. This was not specific 
for DCF, DHF or DSS. 
3. Myalgia, arthralgia and bone pain: 54.60% of the cases had moderate 
to severe myalgia. Most common sites involved were the back, hips and 
lower limbs. The incidence of bone pain which is supposed to be 
characteristic of Dengue, which even gave it the synonym of‖ Break bone 
fever‖, was surprisingly low (3.20%) and was more common in DCF and 
was statistically significant. Arthralgia had occurred in 38.60% of the cases 
and was not specific to DCF, DHF or DSS. 
4. Abdominal Pain: 43.40% cases had abdominal pain which was diffuse, 
non-colicky and vague in character. The severity of abdominal pain was 
more in cases who had associated vomiting. 
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5. Vomiting: 42.20% (106 cases) had vomiting. Vomiting lasted for an 
average of 1.7 days. All the patients with vomiting were treated 
symptomatically. 
Atypical presentation: 
Seizures: 
 Apart from all the above mentioned presenting symptoms, one of the 
most dreadful presentations of dengue during this epidemic was seizure 
(1.20%). Out of 4 patients with dengue encephalopathy 2 patients had 
developed GTCS and 1 patient had seizures following CNS bleed and the 
patient had later succumbed to the disease. 
Analysis of Signs 
 Physical examination in Dengue was done with utmost seriousness so 
that no critical signs that aid in prompt diagnosis of the disease and its 
complications was not missed. The signs were analyzed in detail in the 
present study. The observations are as follows: 
1. Conjunctival congestion due to dilatation of the superficial capillaries 
was the most common sign (23.90 %) noted and was most striking too.  If 
present, it was used as a sign for clinical suspicion of Dengue.  
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2. Rashes: Transient erythematous morbiliform rash (Exanthem) was 
associated in 10% of the cases ( 25 cases ). The spectrum of rash varied from 
erythematous flush that blanched on pressure to exfoliative dermatitis in 1 
case. The rash was associated with itching in 11 cases 
3. Hepatomegaly and Splenomegaly: Clinically hepatomegaly was present 
in 30 cases (12%) and splenomegaly in 21 cases (8.40%). No significance 
was present in statistical analysis and hence these findings could not be 
specifically attributed to DCF, DHF, and DSS. 
4. Ascites: Free fluid abdomen (ascites) was clinically apparent in 30 cases 
(10%). Ascites was a part of third space volume loss due to increased 
capillary leakage more during the later phase of the disease. However ascitic 
fluid analysis was not attempted in these cases for proving the etiology and 
ascites reduced and disappeared with clinical recovery of the patient. Ascites 
was observed in DCF, DHF and DSS. 
5. Pleural effusion: Clinically apparent pleural effusion was present in 24 
cases (9.6%). Clinically right sided pleural effusion was detected more 
frequently followed by bilateral pleural effusion. Pleural fluid analysis was 
not performed in these cases and hence could not be classified as exudative 
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or transudative type . With recovery from the disease, pleural effusion 
subsided and cleared completely. 
6. Puffiness of face: A typical dengue facies resulted from facial puffiness 
especially eye lid edema associated with erythema of the surrounding areas. 
This kind of facial puffiness was present in 21 cases  (8.4%) 
7. Jaundice: 16 cases (6.4%) had icterus associated with dark yellow 
discoloration of urine. However no features suggestive of obstruction of the 
biliary tree were noticed like clay colored stool and pruritis. LFT was done, 
the details of which will be discussed in a later section. 
8. Pneumonia: 4 cases of dengue also had developed pneumonia. This 
pneumonia would have been caused by either a co infection or nosocomial 
infection. Similar cases were observed in the previous studies and WHO had 
opined about the same as above. 
9. Myocarditis:  One of the atypical presentation of dengue observed in the 
present study was myocarditis. Young adults (4 cases) were diagnosed to 
have myocarditis and confirmed with ECHO and treated accordingly. 3 
cases recovered and 1 case succumbed after deteriorating to refractory 
shock. 
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Analysis of Bleeding Manifestations: 
 Studying the bleeding manifestation among the cases admitted was 
undertaken separately. A detailed analysis of various bleeding 
manifestations is as follows. 
A) Melena: 69 cases (27.50%) presented with melena. This was the most 
common bleeding manifestation encountered. DHF and melena were linked 
statistically with significant p value. The severity of melena ranged from 
mild to severe. Majority were self limiting. 5 (2.0%) of them had 
hemetamesis. Massive episodes were treated with blood and blood product 
transfusions. 2 cases who succumbed to the disease had massive episodes of 
melena as a part of the clinical spectrum and later progressed to DIC and 
refractory shock. 
B) Petechiae: 21 cases had petechiae especially over the extremities. Lower 
limbs were commonly involved than the upper limbs may be due to capillary 
damage aggravated on standing by gravity. Petechiae were also noted over 
palate which is an uncommon site for the same. Petechiae were statistically 
significant in DCF. 
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C) Sub-conjunctival hemorrhage: Noted in 14 cases (5.60%), 
subconjuntival hemorrhage was commonly precipated by repeated bouts of 
cough in patients . 
D) Gum bleeding and epistaxis : Mucosal bleeding were common during 
this epidemic.12 cases (4.80%) had gum bleeding and 9 cases (3.60%) had 
epistaxis. All these cases had spontaneous bleeding and some cases had to be 
transfused with blood for replacing the lost volume and for prophylaxis 
against further bleed they were given blood product transfusions. 
E) Menorrhagia: 9 cases of young females admitted with dengue had 
developed menorrhagia during the menstrual cycles and some of them had 
required blood transfusion. 
F) Other bleeding: 4 cases (1.60%) had developed hematuria.1 had 
hemopysis. 
Analysis of Blood Pressure 
 BP is the most important clinical monitor in a case of dengue for 
identifying onset of complications like shock. Pulse pressure is more 
important than BP in identifying early stage shock. Narrowed pulse pressure 
(< 20 mm of Hg) is the most sensitive sign. 
 
 
81 
 
 In this study hypotension was noted at presentation among 54 cases 
and the majority was stabilized using IV fluid support. Hypotension was 
persistent in cases of DSS (26 cases). They had to manage with intense fluid 
therapy according to WHO treatment guidelines. 2 cases that were known 
hypertensives on treatment but admitted in shock had elevated BP at the 
time of discharge and was started on antihypertensives for the same. 
 In our ICU setup we used pulse pressure as the main monitor for 
identifying and treating patients with DSS. 
Analysis of Blood count among cases 
 Thrombocytopenia was the most common abnormality observed. 167 
cases (66.50%) had thrombocytopenia ranging from mild to severe 
thrombocytopenia. Leucopenia was observed in 83 cases (33.10%) and 
strengthened the suspicion of dengue infection and later was confirmed with 
dengue serology. Eosinophilia was observed among many cases mostly in 
patients who had associated dermatological manifestations like rash and 
itching may be as an effect of some allergic response. 
 Haematocrit was elevated in 73 cases studied and they had to be 
treated with IV fluid therapy in addition to oral fluids. Haematocrit was 
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followed up every 6 hours and fluids were titrated accordingly. Haematocrit 
was persistently elevated in 27 cases where the duration of fluid therapy was 
extended to > 48 hours and even 72 hours to normalize the haematocrit. 
WHO recommends fluid therapy only for 48 hours but we had to give IVF 
for an average of 72 hours according to haematocrit. This was a significant 
change in the fluid management strategy that we followed in this epidemic 
and was found to be more effective in treating our population with dengue. 
Further studies dealing with fluid therapy in our population with dengue is 
needed to validate our finding. 
 Low haematocrit was noticed among 58 cases but was significantly 
low in cases who presented with significant bleeding. However a low 
haematocrit was also noted among the cases without bleeding 
manifestations. This may be due to the presence of anemia in these patients 
that might have resulted in low baseline values of haematocrit. Increased 
haematocrit was noted among 38.50% of cases with DSS and was 
statistically significant. 
Analysis of LFT 
 LFT was done in all cases. Normal results were obtained in 137 cases. 
Elevated bilirubin was noted in 27 cases (10.70%). Both direct and indirect 
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bilirubin was increased. However clinically manifest jaundice was present in 
only 16 cases. 
  87 cases showed enzyme abnormalities. All the three enzymes AST, 
ALT and ALP were elevated in 41 cases (47.10%). AST was more elevated 
than ALT in 32 cases and in 5 cases both AST and ALT were elevated in 
almost same proportion. ALT was elevated more than AST in 7 cases. 
Isolated elevation on AST was noticed only in 2 cases. 
 In a study conducted at CMC Vellore, elevation of AST was in 100% 
cases with LFT abnormality which was similar to our study. 
 This elevation of liver enzymes could be  due to direct injury to liver 
cells by the virus  or due to immunological response. Ischemic hepatitis in 
patients especially in shock could be another possible etiology. 
Analysis of ECG findings: 
 Normal recordings were seen in 169 cases. Sinus tachycardia was 
seen in 84 cases mostly due to fever itself and many of them in hypotension 
or shock and tachycardia seemed to resolve with normalization of BP. Sinus 
bradycardia was observed in 29 cases. First degree AV block was seen in 5 
 
 
84 
 
cases and second degree in 2 cases. No case studied had third degree AV 
block. 
Analysis of RFT: 
 Compromised renal function was observed only in 6 cases out of the 
251 cases studied. They belonged to age group < 20 years. However this 
finding was not statistically significant. 
Analysis of USG findings: 
USG abdomen was performed in all cases. The findings are as follows 
 USG abdomen was essentially normal in 104 cases (41.40%) of the 
cases. 
 Gall bladder wall edema was the most common USG finding (60 
cases, 23.90% cases).Hepatomegaly and ascites were present in 39 cases and 
48 cases respectively. 
 Splenomegaly was observed in 38 % cases. Pleural effusion was 
detected in 42 cases (16.70%). 
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Analysis of X-Ray findings:  
 Chest X-ray PA View was normal in 230 cases. Right sided pleural 
effusion was detected in 13 cases and bilateral pleural effusion noted in 6 
cases 
Cardiomegaly was noted only in 1 case. 
 Consolidation was present in 1 case whereas pneumonitis with 
infiltration was reported in 3 cases.  
 On comparing USG and X-ray in diagnosing pleural effusion, USG 
proved to be more sensitive than X-ray. Cases with even mild pleural 
effusion were picked up using USG whereas X-ray revealed normal study.  
 Bilateral pleural effusion was common in USG whereas right sided 
pleural effusion was commonly reported in X-rays. This may be because 
even the minimal pleural effusion on the left side was picked up in USG. No 
patient had isolated left sided pleural effusion. 
 CT brain was performed in patients who had presented with 
encephalopathy and seizures. CT brain was normal in 2 cases. Intracerebral 
bleed was noted in 1 case and minimal white matter hypo density was noted 
in the other case. 
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 Dengue cases were confirmed by serology. NS1 antigen ELISA was 
the most important test used for diagnosing dengue cases in our hospital. 
Dengue IgM and IgG were performed in cases according to the availability 
of test kits. NS1 was found to be positive in 155 cases (61.80%) and IgM 
positive in 112 cases (44.60%). IgG was positive only in 4 cases. 
Analysis of outcome: 
 The cases were admitted and treated in special wards. Cases with DSS 
and DHF were managed in IMCU with intensive fluid therapy. 
 Transfusion with blood and blood products were needed in 190 cases. 
Platelets were not transfused routinely for thrombocytopenia. We used fresh 
whole blood for cases with uncontrolled bleeding. 
 Platelets were transfused in cases with platelet count < 10000/ml or in 
cases with uncontrolled bleeding not responding to whole blood. 
 Regarding the Outcome of dengue epidemic cases admitted in our 
department, Cure rate achieved was 99.20% .We lost 2 cases among the 251 
cases studied. The cause of death was I.C bleed/ encephalopathy/seizures / 
DSS/ DIC / Refractory shock . The other case succumbed due to massive 
malena/encephalopathy/DSS/DIC/refractory shock. 
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SUMMARY 
 251 serologically proven dengue cases were studied from April 2012 
to March 2013. 
 Most of the patient 59.40% belonged to DCF were DHF 30.30% and 
DSS in 10.40%. 
 The most common age group affected was the young adult<20 years 
 Distribution of Dengue & DSS was more common in female gender. 
 Fever was the most prominent symptom followed by headache 
myalgia, abdominal pain and vomiting. 
 Characteristic of dengue like bone pain was present only in 3.2% but 
it has got statistical correlation with DCF. 
 Conjunctival congestion was the most common sign. 
 Atypical feature like encephalopathy, seizures, Myocarditis was also 
observed. 
 Malena was the common bleeding manifestation followed by 
Petechiae, subconjunctival bleeding and Gum bleeding. 
 BP is the most important clinical monitor in a case of Dengue. 
Narrowed pulse pressure (< 20 mm of Hg) is the most sensitive sign 
for identifying early signs of shock. 
 Elevated serum bilirubin was observe in 27 patients and clinical 
jaundice was present in 16 patients. 
 87 patients showed abnormal liver enzymes were SGOT was elevated 
in all 87 patients. 
 USG was more sensitive in picking up Pleural effusion. 
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 Sinus Tachycardia (84) was predominant finding in ECG but sinus 
Bradycardia and various degree of AV blocks was observed. 
 Out of 251 patients  mortality rate was 0.8% 
 Recovery rate was 99.20%. 
 The cause of death was intra cerebral bleed/ encephalopathy/seizures / 
DSS/ DIC / Refractory shock in one case. The other case succumbed due to 
massive malena/encephalopathy/DSS/DIC/refractory shock. 
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CONCLUSION 
 In this study the Clinical Profile of serologically proven Dengue fever 
was studied from April 2012 – March 2013 particularly during the epidemic 
that stormed Tirunelveli district. With this clinical profile it is easy to 
recognize and understand the clinical problem. The application of clinical 
spectrum of WHO classification system is not as very simple and 
straightforward as it seems because clinical features may overlap among 
different categories. The WHO classification system of dengue does not 
include unusual manifestations like encephalopathy, seizures, myocarditis, 
etc, which might be life-threatening. Although these manifestations are rare, 
clinicians should always have a high index of suspicion and knowledge of 
these atypical manifestations, particularly in view of the increasing burden 
of dengue in recent years. Blood pressure and haematocrit should be 
monitored for evaluating for the progress of the disease. Bleeding tendency 
should be closely watched. Management of patients with dengue is mainly 
supportive simple inexpensive and very effective in saving lives 
prophylactic FFP and platelets are not necessary for treating DHF, DSS, but 
early and meticulous monitoring are the corner stone for positive outcome.  
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KEY TO THE MASTER CHART  
 
 Sex: 
 Male:   1 
 Female:   2 
 Symptoms: 
 Fever     :  Yes  1  No  2 
 Chills      :  Yes 1  No 2   
 Retro-orbital pain: Yes 1 No 2 
 Arthralgia               Yes 1 No  2 
 Bone pain               Yes    1 No  2 
 Muscular pain        Yes  1 No 2 
 Nausea  Yes 1 No 2 
 Vomiting  Yes  1 No 2 
 Sore Throat  Yes 1 No 2 
 Seizures  Yes 1 No 2 
 Abdominal pain Yes 1 No 2 
 BP: 
   Normal:   1 
  Low:   2 
  High:   3 
 Pulse Pressure: 
  Normal:   1 
  Low:    2 
 Signs: 
 Icterus  :  Yes 1  No 2 
 Pallor    :  Yes 1 No  2 
 ConjunctivalCongestion:Yes1 No 2 
 Gum Bleeding: Yes 1 No 2 
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 Epistaxis:  Yes 1 No 2 
 Petechiae:  Yes 1 No 2 
 Hemetemesis: Yes 1 No 2 
 Melena:  Yes 1 No 2 
 Hematuria:  Yes 1 No 2 
 Bleeding PR: Yes 1 No 2 
 Bleeding PV: Yes 1 No 2 
 Hepatomegaly: Yes 1 No 2 
 Splenomegaly: Yes 1 No 2 
 Myocarditis: Yes 1 No 2 
 Encephalopathy: Yes 1 No 2 
 Pleural Effusion: 
  Yes-right:   1 
  Yes-Bilateral: 2 
  No:   3 
 Others: 
  Rashes :         1 
  Exfoliative Dermatitis:       2 
  Diarrhoea:         3 
  Neck stiffness, altered sensorium: 4 
  Puffiness of face:        5 
  Breathlessness:        6 
  Pneumonia:          7 
  Loss of apetite:        8 
  Pelvic abscess:        9 
  Herpes Labialis:       10 
  Hemoptysis:        11 
  Subconjunctival haemorrhage:     12 
 Co morbid conditions: 
 CAD:   Yes 1 No 2 
 DM:    Yes 1 No 2 
 HT:    Yes 1 No 2 
 
 
 
112 
 
 Others: 
 Pneumonia:    1 
 HIV:    2 
 TB:    3 
 ANC:    4 
 No:     5 
 USG: 
o Hepatomegaly 
Yes:    1 
o Splenomegaly 
Yes:    1 
o GB Wall Edema 
Yes:    1 
o Ascites 
Yes:    1 
o Normal 
 Yes:    1 
o Pleural effusion: 
 Right only:    1 
 Bilateral:    2 
 Others: 
 Renal calculus:  1 
 Ovarian cyst:   2 
 Fatty liver:    3 
 Right Renal cyst:   4 
 Pericholicedema,:  5 
 Fluid-Morrisons pouch: 5 
 Cholelithiasis:   6 
 Cholecystitis:   7 
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 Loculated pelvic collections: 8 
 Prostatomegaly:    9 
 CBC: 
 Yes:   1 
 No:   2 
 LFT: 
o Enzymes: 
 SGOT,SGPT:  1 
 Alkaline Phosphatase Elevated:1 
 SGOT>SGPT:   2 
 SGPT=SGOT:   3 
 SGPT>SGOT:   4 
 SGOT only:   5 
o Elevated Bilirubin: 
  No:   0  
  Yes :   1 
 RFT: 
 Normal:   1 
 Compromised:  2 
 ECG: 
 Sinus bradycardia:  1 
 Sinus tachycardia:   2 
 Brady with 1st degree AV block: 3 
 Brady with 2nd degree AV block: 4 
  LVH:      5 
  T wave inversion V1- V4:6 
  Normal:      7 
 CXR: 
 Rt pleural effusion:   1 
 Bl pleural effusion:   2 
 Cardiomegaly:    3 
 Rt lower lobe consolidation: 4 
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 CT BRAIN :   
 Not taken:     0 
 Minimal white matter hypodensity: 1 
 Intracerebral bleed:    2 
 Normal:      3 
 
 SEROLOGY : 
o NS1  
 No:  0 
 Yes:  1 
o IgM; 
 No:  0 
 Yes:  1 
o IgG  
 No:  0  
 Yes:  1 
 Rx: 
o TRANSFUSION : 
Whole blood  
 No:  0   
 Yes:   1   
 Platelet:  
 No:  0 
 Yes:  1 
FFP: 
 No:  0 
 Yes:  1 
 
 DIAGNOSIS: 
o DCF 
 No:  0 
  Yes:  1      
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o DHF  
 No:  0  
 Yes:   1      
o DSS      
  No:  0  
 Yes:   1      
o DEATH  
 No:  0  
 Yes:   1      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
116 
 
PROFORMA
 
Name
Sl
. N
o
.
A
ge
Se
x
D
ay
s 
o
f 
st
ay
 in
 h
o
sp
it
al
Fe
ve
r
C
h
ill
s
H
ea
d
 a
ch
e
R
et
ro
-o
rb
it
al
 p
ai
n
A
rt
h
ra
lg
ia
B
o
n
e 
p
ai
n
M
u
sc
u
la
r 
p
ai
n
N
au
se
a
V
o
m
it
in
g
So
ar
 T
h
ro
at
Se
iz
u
re
s
A
b
d
o
m
in
al
 p
ai
n
P
u
ls
e 
R
at
e
B
P
P
u
ls
e 
P
re
ss
u
re
Ic
te
ru
s
P
al
lo
r
C
o
n
ju
n
ct
iv
al
 C
o
n
ge
st
io
n
G
u
m
 B
le
e
d
in
g
Ep
is
ta
xi
s
P
et
ec
h
ia
e
H
em
et
em
es
is
M
el
en
a
H
em
at
u
ri
a
B
le
ed
in
g 
P
R
B
le
ed
in
g 
P
V
H
ep
at
o
m
eg
al
y
Sp
le
n
o
m
eg
al
y
M
yo
ca
rd
it
is
vinoth 1 13 1 7 1 1 1 2 1 1 1 2 1 2 2 1 106 1 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2
sudalaimani 2 14 1 7 1 2 2 2 2 2 1 2 2 2 2 2 112 1 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2
RAJAGOPAL 3 44 1 6 1 2 1 2 1 2 1 1 2 2 2 1 58 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2
PANEER 4 50 1 7 1 1 1 2 1 2 1 2 1 2 2 1 82 1 1 2 2 1 2 2 1 2 1 2 2 2 2 2 2
ANEES 5 28 2 12 1 2 2 2 1 2 1 2 1 2 2 1 74 1 1 2 2 1 2 2 2 2 1 2 2 2 2 2 2
AMBAL 6 42 2 7 1 1 1 2 1 2 1 2 2 2 2 1 110 1 1 2 2 2 2 2 2 2 2 2 2 2 1 2 2
BAKYAM 7 34 2 6 1 1 2 1 2 2 1 1 1 2 2 2 76 1 1 2 2 2 2 2 2 2 1 2 2 2 2 2 2
PECHIMANI 8 18 2 5 1 1 1 1 2 2 1 2 2 2 2 1 88 1 1 2 2 2 2 1 2 2 2 2 2 2 2 2 2
MARI 9 25 2 7 1 2 1 1 2 2 1 1 2 2 2 1 82 1 1 2 2 2 2 2 2 2 1 2 2 2 2 2 2
CHANDRA 10 55 2 7 1 2 1 1 2 2 1 2 2 2 2 1 100 1 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2
ESAKIAMMAL 11 29 2 6 1 2 2 2 2 2 1 1 1 2 2 1 74 1 1 2 2 2 2 2 2 2 1 2 2 2 2 1 2
TAMILSELVI 12 23 2 6 1 2 1 1 2 2 1 2 2 2 2 2 112 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2
USHA 13 27 2 7 1 1 1 1 2 2 1 2 2 2 2 2 106 1 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2
ARUMUGATHAI 14 40 2 7 1 2 1 1 2 2 1 2 2 2 2 2 104 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
RAJAKUMARI 18 26 2 7 1 2 2 2 2 2 1 1 2 2 2 1 107 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
SADALI 19 55 2 6 1 1 1 1 1 1 1 1 1 2 2 1 60 3 1 2 1 1 2 2 2 2 2 2 2 2 2 2 2
mahalakshmi 20 30 2 4 1 1 1 2 2 2 1 1 1 2 2 2 84 1 1 2 2 1 2 2 1 2 2 2 2 2 2 2 2
SHAJAHAN 21 34 1 6 1 1 1 2 1 2 1 2 2 2 2 2 112 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 1
SARATHY 22 17 1 6 1 1 1 1 1 2 2 2 1 2 2 2 110 2 1 2 2 2 1 2 2 2 2 2 2 2 2 2 2
SARAVANAN 23 18 1 5 1 2 2 2 2 2 1 2 1 2 2 2 106 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2
siriyapuspam 24 18 2 5 1 1 1 1 1 2 1 2 1 2 2 2 109 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
rajasekar 25 54 1 5 1 2 1 2 1 2 1 2 1 1 2 2 112 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
RENGANATHAN 27 20 1 6 1 1 1 2 1 2 1 2 2 2 2 1 60 2 2 1 2 2 2 2 2 2 2 2 2 2 2 1 2
PRIYA 29 26 2 6 1 1 2 2 2 2 2 1 2 1 2 1 100 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
PETCHIAMMAL 30 20 2 6 1 1 2 2 1 2 1 2 1 2 2 1 114 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
KARUNYA 31 22 2 6 1 2 2 2 2 2 2 2 2 2 2 1 88 1 1 2 2 1 2 2 2 2 1 1 1 1 2 2 2
JEYACHANDRAN 32 24 1 6 1 2 1 2 2 2 1 1 1 2 2 1 54 1 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2
KANNAN 33 19 1 7 1 1 1 2 2 2 2 2 2 2 2 2 90 1 1 2 2 2 2 2 2 2 1 2 2 2 1 2 2
mariyaraj 34 20 1 5 1 1 1 1 2 2 1 2 1 1 2 2 120 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
ESAKIAMMAL 36 15 2 9 1 1 1 1 2 2 1 2 1 2 2 2 110 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2
PRIYA 38 16 2 5 1 1 1 2 2 2 1 2 2 1 2 1 84 1 1 2 2 2 2 1 2 2 2 2 2 2 2 2 2
RAMALAKSHMI 39 17 2 8 1 1 1 1 2 2 2 2 2 2 2 2 110 1 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2
GAYATHIRI 40 24 2 6 1 2 2 2 2 2 1 1 2 2 2 2 105 1 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2
SUMATHY 41 14 2 4 1 2 1 2 2 2 1 2 2 2 2 2 108 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2
aasir samraj 43 14 1 5 1 1 1 2 2 2 2 1 1 2 2 1 109 1 1 2 2 2 2 2 2 2 2 2 2 2 1 2 2
KRISHNA 44 19 1 8 1 1 1 1 2 2 2 2 1 1 2 1 60 1 1 2 2 2 2 1 2 2 2 2 2 2 1 2 2
ANBARASI 45 16 2 7 1 1 2 2 1 2 1 2 2 2 2 1 114 1 1 1 2 1 2 2 2 2 2 2 2 2 2 2 2
Symptoms and signs
AJITH 46 15 1 6 1 1 1 2 2 2 2 1 1 2 2 2 118 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
LAKSHMI 47 37 2 10 1 2 2 2 1 2 1 2 2 2 2 2 104 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
BIRTHOUS 48 32 2 6 1 1 1 2 2 2 2 2 2 2 2 1 112 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
BALASUBRAMANIAN 49 22 1 4 1 1 1 1 2 2 2 2 2 2 2 2 56 1 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2
DHARMAR 51 55 1 6 1 2 1 2 1 2 1 1 1 2 2 1 80 1 1 2 2 2 2 1 2 2 2 2 2 2 2 1 2
ESAKIRAJ 52 13 1 5 1 1 2 2 2 2 2 1 1 1 2 2 103 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
SUDALAI SELVI 53 16 2 4 1 2 2 2 2 2 1 1 2 2 2 2 100 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
VANI 54 24 2 6 1 1 1 2 2 2 2 2 1 1 2 1 82 1 1 2 2 2 2 1 1 1 2 2 2 2 2 2 2
GOMATHI 55 60 2 12 1 2 1 2 2 2 1 2 2 2 2 1 103 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
KAVITHA 56 14 2 4 1 1 1 2 1 2 1 1 1 2 2 2 109 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
BALASUBRAMANI 57 13 1 7 1 2 2 2 1 2 2 2 2 2 2 2 102 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
KUMARESAN 59 19 1 6 1 1 2 2 1 2 1 2 2 2 2 2 100 1 1 2 2 2 2 2 2 2 1 2 2 2 2 2 2
KARTHIKEYAN 60 32 1 5 1 2 2 2 2 2 2 2 2 2 2 2 120 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
KOKILA 61 13 2 6 1 2 1 2 2 2 1 2 2 1 2 2 114 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
SANDHYA 62 15 2 6 1 2 1 2 2 2 1 2 2 2 2 2 110 1 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2
LAKSHMI 63 55 2 5 1 2 1 2 2 2 1 2 2 2 2 2 112 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
SUBBHU 64 50 2 6 1 2 2 2 2 2 1 2 2 2 2 1 62 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
GOMATHI 65 14 2 5 1 2 1 1 2 2 1 2 2 2 2 2 104 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
BHUVANESWARI 66 14 2 5 1 2 2 2 2 2 1 2 2 2 2 2 78 1 1 1 2 2 2 2 2 2 1 2 2 2 2 2 2
ISAKI 67 30 1 3 1 2 1 1 1 2 1 2 2 2 2 2 100 1 1 2 2 1 2 2 2 2 2 2 2 2 2 2 1
KARUMARI 69 14 2 6 1 2 1 1 2 2 2 2 2 2 2 2 103 1 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2
MAHARAJA 71 18 1 6 1 2 1 2 1 2 1 2 2 2 2 2 107 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
AYYADURAI 73 29 1 6 1 1 1 2 2 2 1 2 2 2 2 2 90 1 1 2 2 2 2 2 2 2 1 2 2 2 2 2 2
KODIMALAR 74 23 2 6 1 1 1 2 2 2 2 2 1 2 2 1 54 2 2 2 2 2 1 2 2 2 2 2 2 1 2 2 2
RAJKUMAR 75 16 1 7 1 2 2 2 2 2 2 2 2 1 2 1 106 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
PATTU 76 17 2 6 1 2 1 2 2 2 2 2 2 2 2 2 64 1 1 2 2 2 1 2 1 2 2 2 2 2 2 2 2
VELAMMAL 77 35 2 4 1 2 2 2 1 1 2 2 2 2 2 2 102 1 1 2 2 2 2 2 2 2 2 2 2 2 1 2 2
AYYAMMAL 78 17 2 5 1 2 2 2 2 2 2 1 1 2 2 2 110 1 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2
MARIAMMAL 79 23 2 4 1 2 1 1 1 2 2 2 1 2 2 2 108 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
LAKSHMANAN 80 49 1 6 1 2 2 2 2 2 2 2 2 2 2 1 100 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
ISAKIAMMAL 81 35 2 6 1 1 2 2 1 2 1 2 2 2 2 1 108 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
ISWARIYA 83 14 2 7 1 1 2 2 2 2 2 2 1 2 2 2 100 1 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2
INDHUMATHI 84 16 2 6 1 1 2 2 2 2 2 2 2 2 2 2 112 1 1 2 2 2 2 2 2 2 2 2 2 2 1 2 2
ABRAHAM 85 50 2 10 1 1 2 2 2 2 2 2 2 2 2 2 62 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
SHAKTHIMURUGAN 86 15 1 6 1 1 2 2 2 2 2 2 2 1 2 2 104 1 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2
KATHIJA BEEVI 87 23 2 6 1 2 1 1 2 2 2 2 1 2 2 1 60 3 1 2 2 1 2 2 2 2 2 2 2 2 1 2 2
GNANAMOORTHY 88 14 1 5 1 1 1 1 1 2 2 2 1 2 2 1 90 1 1 2 2 2 2 2 2 2 1 2 2 2 2 2 2
RAMALAKSHMI 89 16 2 5 1 1 1 2 2 2 2 2 2 2 2 2 46 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
THANALAKSHMI 90 15 2 10 1 2 2 2 2 2 1 2 2 2 2 1 106 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
BHARATH 91 21 1 6 1 1 2 2 2 2 2 2 1 2 2 1 100 1 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2
PATTAMUTHU 92 40 1 6 1 2 1 2 2 2 2 2 1 2 2 2 101 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
RAMALAKSHMI 93 28 2 5 1 2 1 2 1 2 1 2 1 2 2 2 82 1 1 2 2 2 2 2 2 2 1 2 2 2 2 2 2
NARAYANAN 94 17 1 6 1 1 1 1 1 1 2 1 1 2 2 1 109 1 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2
VEERAPANDI 95 35 1 6 1 1 1 2 1 2 1 2 2 2 2 1 101 2 1 2 2 1 2 2 2 2 2 2 2 2 1 2 2
KARUPPAIAH 96 42 1 6 1 1 1 1 2 2 2 2 1 2 2 2 109 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
ISAKKIAMMAL 97 40 2 5 1 1 1 2 1 2 2 2 2 2 2 2 103 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
ANITHA 98 18 2 6 1 1 2 2 2 2 2 2 1 2 2 2 102 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
RAMKUMAR 99 14 1 5 1 2 2 2 1 2 1 2 1 2 2 1 109 1 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2
KRISHNAMOORTHY 100 17 1 6 1 1 1 2 1 2 2 2 2 2 2 2 105 1 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2
SHANMUGAVADIVU 101 38 2 5 1 1 1 1 1 1 2 2 2 2 2 1 120 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
MARISELVI 102 15 2 10 1 2 1 2 2 2 1 2 2 2 2 2 100 1 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2
STALIN 103 17 1 5 1 2 2 2 1 1 2 2 2 2 2 2 109 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 1
SANKARESWARI 104 22 2 7 1 2 2 2 2 2 2 2 1 2 2 1 101 2 1 2 2 2 2 2 2 2 1 2 2 2 2 1 2
PARVATHI 106 27 2 7 1 1 1 2 2 2 1 2 2 2 2 1 72 1 1 2 2 2 2 2 1 2 1 2 2 2 2 1 2
NANDHINI 107 15 2 7 1 2 2 1 2 2 1 2 2 2 2 1 100 2 1 2 2 2 2 2 1 2 2 2 2 1 2 2 2
MERLIN 109 24 2 7 1 1 1 2 1 2 1 2 2 1 2 2 120 1 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2
MURUGESH 112 15 1 10 1 2 2 1 1 2 1 2 2 2 2 2 118 2 2 2 2 1 2 2 2 2 1 2 2 2 2 2 2
MARIAMMAL 113 13 2 8 1 2 2 2 1 2 1 1 2 2 2 1 92 2 1 2 2 2 2 2 1 2 1 2 2 2 2 2 2
MICHAEL 114 27 1 10 1 1 1 2 1 2 1 2 2 2 2 2 110 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
RAJESHWARI 115 15 2 12 1 1 1 2 2 2 2 2 2 2 2 2 118 2 1 2 2 1 2 2 1 2 2 2 2 1 2 2 2
MAHALINGAM 116 75 1 8 1 1 1 1 2 2 2 2 2 2 2 2 86 1 1 2 2 2 2 2 1 2 1 2 2 2 2 2 2
PETCHIDURAI 117 17 1 9 1 1 2 2 2 2 2 2 2 2 2 2 103 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
MAYAKRISHNAN 118 35 1 7 1 2 2 2 2 2 1 2 2 2 2 1 48 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
PETER 120 54 1 5 1 1 1 2 2 2 2 1 1 2 2 1 110 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2
POOLIAH 121 30 1 7 1 2 1 1 2 2 2 2 2 2 2 2 113 2 2 2 2 2 2 2 2 2 1 2 2 2 1 2 2
MURUGAIAH 122 65 1 6 1 2 2 2 2 2 2 2 2 1 2 2 72 1 1 2 2 2 2 2 2 2 1 2 2 2 2 2 2
DEVI 124 25 2 5 1 1 2 2 2 2 2 2 1 1 2 1 52 1 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2
PALANI 125 25 1 5 1 1 1 2 1 2 2 1 2 2 2 2 112 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
nallammal 126 48 2 4 1 2 1 2 1 2 1 1 2 2 2 1 119 2 1 2 2 2 2 2 2 2 1 2 2 2 2 2 2
PREMKUMAR 127 22 1 9 1 2 2 2 2 2 2 2 1 2 2 2 100 2 1 2 2 2 2 2 2 2 1 2 2 2 1 2 2
PRAKASH 129 21 1 5 1 1 1 1 1 2 1 2 2 2 2 2 90 1 1 2 2 1 2 1 2 2 2 2 2 2 2 2 2
pitchammal 130 55 2 4 1 2 1 1 1 2 1 2 1 2 2 1 56 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
CHANDRALEKHA 131 24 2 4 1 2 1 1 1 2 1 2 2 2 2 2 72 1 1 2 2 1 2 2 1 2 2 2 2 2 2 2 2
CHINNATHAI 132 24 2 5 1 2 1 1 2 2 2 2 2 2 2 1 96 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
SIVA 133 17 2 1 1 2 1 2 1 2 1 2 2 2 1 2 112 2 2 2 2 1 1 2 2 1 2 2 2 2 2 2 2
CHELLAMMAL 134 50 2 6 1 2 1 2 2 2 1 1 2 2 2 2 98 2 1 2 2 1 1 2 2 1 2 2 2 1 2 2 2
SUGANTHI 136 18 2 6 1 2 1 2 2 2 2 2 1 2 2 2 52 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
SUBRAMANIYAN 138 21 1 5 1 2 1 1 2 2 2 2 1 2 2 1 82 1 1 2 2 2 2 1 2 2 1 2 2 2 2 2 2
NIYAS AHAMED 139 15 1 8 1 2 2 2 2 2 1 2 2 2 2 1 96 1 1 2 2 2 2 2 2 2 1 2 2 2 2 2 2
SELVAKUMAR 140 14 1 5 1 2 2 2 1 2 1 2 2 2 2 2 50 2 1 2 2 2 2 2 2 2 1 1 2 2 2 2 2
SHUNMUGAIAH 141 65 1 6 1 1 2 2 2 2 2 2 1 2 2 2 68 1 1 2 2 2 2 2 2 2 1 2 2 2 2 2 2
SORNAM 142 35 2 13 1 1 1 2 2 2 1 2 1 2 2 1 98 1 1 2 2 2 2 2 2 2 2 2 2 2 1 1 2
SARAVANAN 143 15 1 6 1 2 2 2 2 2 1 2 2 2 2 2 80 2 1 2 2 1 2 2 2 2 1 2 2 2 2 2 2
MARISELVI 144 29 2 7 1 1 2 2 2 2 2 2 2 2 2 2 72 1 1 2 2 2 2 2 2 2 1 2 2 2 1 2 2
KARUPPASAMY 146 50 1 3 1 2 2 2 1 2 2 2 1 2 2 2 72 1 1 2 2 2 2 2 1 2 1 2 2 2 1 2 2
SHUNMUGASUNDARAM 147 19 1 7 1 1 2 2 2 2 2 2 1 2 2 1 110 2 1 2 2 2 2 2 2 2 1 2 2 2 2 2 2
ANITHA 148 20 2 5 1 1 2 2 2 2 1 2 1 1 2 2 112 2 1 2 2 2 1 2 2 2 2 2 2 1 2 2 2
MAYILMURUGAN 150 13 1 8 1 2 2 2 1 2 1 2 2 2 2 2 73 1 1 2 2 2 2 2 2 2 1 2 2 2 2 2 2
SIVARANCHANI 151 15 2 7 1 1 2 2 2 2 2 2 1 2 2 2 110 2 1 2 2 1 2 1 2 2 2 2 2 2 2 2 2
RAGHU 152 26 1 5 1 2 1 2 1 2 2 2 1 1 2 2 80 1 1 1 2 2 2 2 2 2 1 2 2 2 2 2 2
RAMASAMY 153 45 1 4 1 1 2 2 2 2 2 2 2 2 2 2 80 1 1 2 1 2 2 2 2 2 1 2 2 2 2 2 2
SORIMUTHU 155 25 1 6 1 2 1 2 1 2 1 2 1 2 2 2 104 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
saamundeswari 156 22 2 4 1 2 2 2 1 2 1 1 2 2 2 2 98 1 1 2 1 2 2 2 2 2 1 2 2 2 2 2 2
DELSI 158 13 2 4 1 2 2 2 2 2 2 2 1 1 2 2 110 2 1 2 2 2 2 2 2 2 1 2 2 2 2 2 2
SHUNMUGAM 159 60 1 7 1 2 2 2 2 2 1 2 1 2 2 1 84 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
SHARMILABANU 160 31 2 11 1 2 2 2 2 2 2 2 1 2 2 2 112 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
SASIKUMAR 161 19 1 8 1 2 1 2 2 2 1 2 1 2 2 1 80 1 1 1 2 2 2 2 2 2 2 2 2 2 1 2 2
SUGANYA 162 16 2 5 1 2 2 2 2 2 2 2 1 2 2 1 92 1 1 2 2 2 2 2 2 2 1 2 2 2 2 2 2
ILAIYAPERUMAL50 165 50 1 9 1 1 1 2 2 2 1 2 2 2 2 2 60 3 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
KAMALESH 166 13 1 4 1 1 2 2 1 2 1 2 2 2 2 2 100 2 1 2 2 1 2 2 2 1 2 2 2 2 1 2 2
MUTHULAKSHMI 167 27 2 10 1 2 2 2 2 2 2 2 1 2 2 2 84 1 1 2 2 2 2 2 2 2 1 2 2 2 2 2 2
GANDHI 168 47 1 6 1 2 1 2 2 2 1 2 1 2 2 2 82 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
VIGNESH 169 17 1 5 1 2 1 2 2 2 1 2 2 2 2 2 76 1 1 2 2 2 2 2 2 2 2 2 2 2 1 1 2
SELVI 171 16 2 6 1 1 1 2 2 2 1 2 1 2 2 2 78 1 1 2 2 2 2 2 2 2 1 2 2 2 2 2 2
SHEIKMOHAMMED 172 16 1 9 1 1 1 1 1 2 2 2 2 2 2 2 102 1 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2
SAMDURAI 174 17 1 5 1 2 1 2 1 2 1 1 2 2 2 1 98 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
ANAND 175 26 1 7 1 1 1 2 2 2 2 2 2 2 2 2 82 1 1 2 2 2 2 2 2 2 2 2 2 2 1 2 2
ABDULKATHAR 176 45 1 5 1 2 1 2 1 2 2 2 1 2 2 2 74 1 1 2 2 2 2 2 2 2 2 2 2 2 1 2 2
AMEEN 177 13 1 5 1 1 1 2 1 2 1 2 2 2 2 2 110 2 1 2 2 2 2 2 2 2 1 2 2 2 2 2 2
MYDEEN 179 24 1 4 1 2 2 2 2 2 2 2 2 2 2 2 98 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
SELVARAJ 181 23 1 4 1 2 2 2 1 2 1 2 2 1 2 2 70 1 1 2 2 2 2 2 1 2 1 2 2 2 2 2 2
MANIKANDAN 182 40 1 6 1 2 1 1 2 2 2 2 2 1 2 1 50 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2
FASID 183 13 1 7 1 2 2 1 1 2 1 2 2 2 2 2 80 1 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2
LAKSHMANAN 184 45 1 5 1 2 2 2 2 2 2 2 2 2 2 1 92 1 1 2 2 2 2 2 2 2 1 2 2 2 2 2 2
NAMEETHAL BEEVI 185 55 2 7 1 2 2 2 1 2 1 1 2 2 2 1 86 1 1 1 2 2 2 2 2 2 2 2 1 2 2 2 2
ALAMEEN 186 22 1 5 1 2 1 2 1 2 2 2 2 2 2 2 88 1 1 2 2 2 2 2 1 2 2 2 2 2 2 2 2
ABHINESH 189 21 1 8 1 2 1 1 1 2 2 2 1 2 2 2 92 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2
SAMI 190 24 1 13 1 1 1 2 1 2 1 2 1 2 2 2 82 1 1 2 2 1 2 1 2 2 2 2 2 2 2 2 2
VALARMATHI 191 22 2 4 1 1 1 1 2 1 2 2 1 2 2 2 88 3 1 2 2 2 2 2 2 2 2 2 2 1 2 2 2
KARPAGAM 192 30 2 4 1 1 1 2 2 2 2 2 1 2 2 1 82 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
ESAKIMUTHU 193 27 1 5 1 1 1 1 2 2 2 2 1 1 2 1 80 1 1 2 2 2 2 2 2 2 1 2 2 2 2 2 2
MURUGAN 195 39 1 7 1 1 1 1 2 2 2 2 2 2 2 1 86 1 1 2 2 2 2 2 2 2 2 2 2 2 1 1 2
SYED MAZOODU 196 55 1 8 1 2 1 1 1 2 2 2 2 2 2 2 84 1 1 2 2 2 1 2 2 2 1 2 2 2 2 2 2
BASKARAN 197 29 1 4 1 1 1 2 2 2 2 2 2 2 2 2 82 1 1 2 2 2 2 2 2 2 1 2 2 2 2 2 2
PATTUKUMAR 201 17 1 8 1 2 1 1 2 2 2 2 1 2 2 1 78 1 1 2 2 2 2 2 2 2 1 2 2 2 1 1 2
SOLAI AMMAL 202 18 2 6 1 2 2 2 2 2 2 2 1 2 2 1 106 2 1 2 2 2 2 2 2 2 2 2 2 1 1 2 2
MURUGAN 203 47 1 7 1 1 1 1 1 2 2 2 2 1 2 1 82 1 1 2 2 2 2 2 2 2 1 2 2 2 1 1 2
BULA 204 19 2 7 1 2 1 1 2 2 1 2 2 2 2 1 108 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
KARTHIKEYAN 206 17 1 6 1 2 1 1 2 2 1 2 2 2 2 2 82 1 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2
RAMAN 207 25 1 5 1 1 2 2 2 2 2 2 2 1 2 2 58 1 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2
RAJENDRAN 209 50 1 9 1 1 2 2 1 2 1 2 2 2 2 1 60 1 1 2 2 2 2 2 2 2 1 2 2 2 2 2 2
SAMEERA BANU 210 18 2 4 1 1 1 1 2 2 2 1 1 2 2 1 96 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
GOPALA KRISHNAN 212 21 1 10 1 1 1 1 2 2 1 2 2 2 2 1 52 1 1 2 2 2 2 2 2 2 1 2 2 2 2 2 2
KOVIL RAJ 214 22 1 6 1 1 1 2 1 2 2 2 2 1 2 2 44 1 1 2 2 2 1 2 2 2 2 2 2 2 2 2 2
ARUMUGAM 215 43 1 9 1 2 1 1 1 2 1 2 2 2 2 2 88 1 1 2 2 2 2 2 2 2 1 2 2 2 2 2 2
SORNAMALA 217 42 2 5 1 2 2 2 2 2 2 2 2 1 2 2 78 1 1 1 2 1 2 2 2 2 2 2 2 2 2 2 2
USHA 218 23 2 9 1 2 1 1 2 2 2 2 2 1 2 2 76 1 1 2 2 2 1 2 2 2 2 2 2 2 2 2 2
UDHAYAKUMAR 219 13 1 4 1 2 1 1 2 2 1 2 1 1 2 1 56 1 1 2 2 2 2 2 2 2 1 2 2 2 2 2 2
ANANDHI 222 17 2 10 1 2 2 2 1 2 1 2 2 2 2 1 78 1 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2
UMA 223 37 2 5 1 1 1 1 1 2 1 2 2 2 2 2 82 1 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2
KAJA MYDEEN 224 20 1 7 1 2 2 2 1 2 1 2 2 2 2 2 75 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
SREEBANU 226 18 2 5 1 2 1 1 2 2 2 2 1 2 2 1 86 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
RAHEELA 227 17 2 7 1 1 1 1 1 2 1 1 1 1 1 1 82 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
MANIMARAN 229 16 1 5 1 2 2 2 1 2 1 2 1 2 2 2 72 2 2 1 1 1 2 2 2 2 2 2 2 2 2 2 2
SURESH 230 20 1 6 1 1 1 1 1 2 1 2 1 1 2 1 90 1 1 2 2 2 2 2 2 2 2 2 2 2 1 2 2
SINTHANISHA 231 15 2 4 1 1 1 2 1 2 1 2 2 2 2 1 84 1 1 2 2 2 1 2 2 2 2 2 2 2 2 2 2
SARASWATHY 232 27 2 5 1 1 1 1 1 2 1 2 1 2 2 2 96 1 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2
MANIKANDAN 233 17 1 6 1 1 1 1 2 2 1 2 2 2 2 2 86 1 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2
SANKARI 235 23 2 6 1 1 1 1 2 2 2 2 1 2 2 1 92 1 1 2 2 2 2 2 2 2 1 2 2 2 2 2 2
SELVI 236 31 2 5 1 1 2 2 1 2 1 2 2 1 2 2 86 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
SRIPAUL 237 23 1 8 1 2 1 2 1 2 1 2 2 2 2 2 50 1 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2
NAJIMA 238 17 2 5 1 2 1 1 2 2 2 2 1 1 2 1 82 1 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2
PREMRAJ 239 29 1 6 1 1 1 1 1 2 1 2 2 1 2 2 92 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
ROHINI 240 14 2 8 1 1 2 2 1 2 1 2 1 1 2 1 44 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
SARAVANAN 241 22 1 7 1 2 2 2 1 2 1 2 2 2 2 2 92 1 1 2 2 1 2 2 2 2 1 2 2 2 1 1 2
VELTHAI 244 23 2 3 1 2 1 1 1 2 1 2 2 2 2 2 80 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
SAKTHI 245 23 2 3 1 1 1 1 1 2 1 1 2 2 2 2 48 1 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2
KALIAMMAL 246 28 2 9 1 2 1 2 1 2 1 2 1 2 2 1 88 1 1 2 2 2 2 2 2 2 1 2 2 2 1 2 2
MUTHUSELVI 249 21 2 6 1 2 2 2 2 2 1 2 1 2 2 1 82 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
ANANDHA SELVI 250 14 2 5 1 1 1 1 2 2 2 2 2 2 2 1 48 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
JAMERLA 15 23 2 5 1 2 2 2 1 2 1 2 2 2 2 2 86 1 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2
CHANDRASEKAR 26 20 1 5 1 1 1 2 2 2 2 2 1 2 2 2 74 1 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2
VELAMMAL 28 45 2 6 1 1 1 2 2 2 1 2 2 2 2 1 78 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
MALLIKA 37 18 2 4 1 2 1 1 1 1 1 2 1 2 2 1 98 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
ANU 42 28 2 6 1 2 1 1 1 2 1 1 2 1 2 1 54 1 1 2 2 2 2 2 2 2 1 2 2 2 2 2 2
KAPILKUMAR 58 16 1 6 1 2 2 2 2 2 2 1 1 1 2 1 90 1 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2
PRABHAKARAN 68 22 1 5 1 1 2 2 2 2 1 1 2 2 2 2 86 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
DIVYA 72 18 2 5 1 2 1 2 2 2 2 2 1 2 2 2 78 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
MARI 111 17 2 10 1 2 2 2 2 2 2 2 1 2 2 2 82 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
prasanth 119 17 1 4 1 2 2 2 2 2 1 2 2 2 2 2 100 2 1 2 2 1 2 2 2 2 2 1 2 2 2 2 2
PALMANI 128 24 2 3 1 1 1 2 2 2 2 1 2 2 2 2 82 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
SHAJAHAN 135 40 1 9 1 2 2 2 2 2 2 2 2 2 2 2 82 1 1 2 2 2 2 2 1 2 1 2 2 2 2 2 2
BRAHAMACHI 149 50 2 10 1 2 1 2 2 2 1 2 2 2 2 2 128 2 1 2 2 1 2 2 2 2 1 1 2 2 1 2 1
RAJAMMAL 154 45 2 6 1 2 2 2 2 2 2 2 2 2 2 1 116 2 1 2 2 2 1 2 2 2 2 2 2 2 2 2 2
AMALA ANTO 188 13 2 6 1 2 2 1 2 2 1 2 2 2 2 1 100 1 1 2 2 2 2 2 2 2 1 2 2 2 2 2 2
SENTHOOR KANI 194 30 2 5 1 2 1 1 2 2 2 2 1 2 2 2 60 2 1 2 1 2 2 2 2 2 1 2 2 2 2 2 2
VALLI 198 25 2 5 1 2 1 1 2 2 2 2 1 2 2 2 86 1 1 2 2 1 2 2 2 2 1 2 2 2 2 2 2
CHAKARAVARTHY 200 17 1 8 1 2 1 1 2 2 2 2 1 2 2 2 98 1 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2
MURUGAN 205 30 1 7 1 1 1 2 1 2 1 2 1 2 2 1 82 1 1 2 2 1 2 2 1 2 2 2 2 2 2 2 2
FATHIMA 208 17 2 5 1 1 1 1 2 2 1 2 2 2 2 1 48 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
KULANTHAI RAJ 213 55 1 10 1 1 1 1 1 2 1 2 1 2 2 1 120 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
AJAY 216 14 1 6 1 1 2 2 1 2 1 2 2 2 2 2 106 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
ISAKIRAJA 225 13 1 5 1 1 1 1 1 2 1 2 1 2 2 1 76 1 1 2 2 2 2 2 2 2 2 2 2 2 1 2 2
MADASAMY 228 15 1 6 1 2 2 2 2 2 2 2 2 2 2 2 76 1 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2
MARIAPPAN 251 19 1 5 1 2 1 1 2 2 1 2 2 2 2 2 72 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
GOHILA 16 25 2 4 1 2 2 2 1 2 1 2 2 2 2 1 90 1 1 2 1 1 2 2 2 2 2 2 2 2 2 2 2
MOHAMMED 17 17 1 8 1 2 1 1 2 2 1 2 2 2 2 1 82 1 1 2 2 1 2 2 1 2 2 2 2 2 2 2 2
MATHUMATHI 35 13 2 5 1 2 1 1 2 2 2 2 1 2 2 1 88 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
CHANDRASEKAR 50 27 1 7 1 2 2 2 2 2 1 2 2 1 2 2 80 1 1 2 2 2 2 2 1 2 2 2 2 2 2 2 2
ARUMUGAM 70 19 1 5 1 1 1 2 2 2 1 2 2 1 2 1 84 1 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2
GNANAPOO 82 52 2 5 1 2 2 2 2 2 1 2 1 2 2 2 88 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
PATTAMMAL 105 35 2 7 1 1 1 1 2 2 1 2 2 2 2 2 76 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
MARI 123 25 2 6 1 2 2 2 2 2 1 2 1 2 2 2 80 1 1 2 2 2 2 2 1 2 1 2 2 2 2 2 2
ALAVUDEEN 137 17 1 5 1 2 1 2 1 2 1 2 1 2 2 1 86 1 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2
SONIAGANDHI 170 23 2 6 1 1 2 2 2 2 2 2 2 2 2 1 88 1 1 2 2 1 2 2 2 2 1 2 2 2 2 2 2
SUMATHY 199 28 2 4 1 1 1 1 1 2 1 2 2 2 2 1 76 1 1 2 2 2 2 2 1 2 2 2 2 2 2 2 2
SUBASH 220 13 1 2 1 1 2 2 2 2 2 2 1 2 2 2 110 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2
JASIMVICTOR 221 17 1 9 1 1 1 1 1 2 1 2 1 2 2 1 106 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
SEKAR 234 40 1 6 1 2 1 1 2 2 2 2 1 2 2 1 90 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
SUDALAIMANI 242 35 1 6 1 1 1 1 1 2 1 2 1 1 2 1 88 1 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2
SANGEETHA 247 19 2 7 1 1 2 2 2 2 2 2 1 2 2 1 52 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
DEVIKALA 248 25 2 6 1 1 2 2 2 2 2 2 1 2 2 1 74 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
SARASWATHI 108 31 2 9 1 2 1 1 2 2 2 2 2 2 1 2 107 2 1 2 2 2 2 2 1 1 1 2 2 2 2 2 2
ARUN 164 20 1 6 1 1 1 2 1 2 1 1 1 2 2 1 80 1 1 2 2 2 2 2 2 2 1 2 2 2 1 2 2
MOHAMMEDRAHIM 163 30 1 4 1 1 2 2 2 2 2 1 1 2 2 1 62 3 1 1 2 1 2 2 2 2 1 2 2 2 2 2 2
MADASAMY 110 27 1 7 1 2 2 1 1 2 1 2 2 2 2 2 88 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2
RAJESWARI 157 36 2 7 1 2 1 2 1 2 1 2 2 2 2 1 86 1 1 2 2 1 2 2 2 2 1 2 2 2 2 2 2
SENTHIL 173 21 1 6 1 2 1 2 2 2 2 1 1 1 2 2 72 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
MALATHI 178 15 2 5 1 1 1 2 2 2 2 1 1 1 2 2 98 1 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2
MURUGAN 180 42 1 6 1 2 2 2 1 2 2 2 2 2 2 1 100 1 1 1 2 2 2 2 2 2 1 2 2 2 2 2 2
LAKSHMI 187 16 2 14 1 2 1 2 2 2 2 2 1 2 2 1 120 2 1 1 1 2 2 2 2 2 1 2 2 1 2 2 2
KANAGA 211 18 2 7 1 1 1 1 1 2 2 2 1 2 2 1 94 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
ANGEL 243 48 2 10 1 2 1 2 2 2 2 2 2 2 2 2 85 1 1 2 2 2 2 2 2 2 2 2 2 2 1 2 2
NAMBIAMMAL 145 37 2 6 1 1 2 2 2 2 2 2 1 2 2 1 48 2 1 2 2 1 2 2 1 2 1 2 2 2 1 1 2
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3 2 2 5 2 2 2 5 1 2 1 1 1 2 1 1 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 2 1 1 1 2 0 1 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 1 1 2 1 1 1 1 1 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 1 1 3 1 7 1 1 0 0 0 1 1 12 1 0
3 1 2 0 2 2 2 5 1 1 1 1 2 1 7 1 0 0 0 0 1 1 12 1 0
3 2 2 0 2 2 2 1 1 1 1 3 1 2 2 1 0 0 4 0 0 1 0
3 2 2 0 2 2 2 5 1 1 1 3 1 7 0 1 0 0 0 1 1 1 0
3 2 2 0 2 2 2 5 1 2 1 3 1 7 0 1 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 1 1 3 1 7 1 0 0 0 0 1 1 12 1 0
1 2 2 0 2 2 1 5 1 1 2 1 3 1 1 2 1 1 0 1 0 1 2 1 0
3 2 2 0 2 2 2 5 1 2 1 2 1 7 0 1 0 0 0 1 1 1 123 1 0
1 1 2 12 2 2 2 5 1 1 2 1 3 1 3 2 0 1 0 1 0 1 1 12 1 1 0
3 2 2 0 2 2 2 5 1 1 2 1 1 2 1 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 2 2 1 1 2 0 1 0 0 0 0 1 0
3 2 2 0 2 2 2 5 2 2 1 1 1 2 1 0 0 0 0 0 1 0
3 2 2 0 2 2 1 5 1 1 1 3 1 1 0 1 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 1 1 3 1 7 1 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 2 1 2 1 3 2 1 0 0 0 0 0 1 0
3 2 2 12 2 2 2 5 1 2 1 3 1 1 2 0 1 0 0 0 1 1 1 0
2 1 2 0 2 2 2 5 1 2 1 2 1 2 1 4 1 2 0 1 0 2 0 0 1 0
3 2 2 5 2 2 2 5 1 1 1 1 1 2 2 1 0 0 0 0 0 1 0
3 2 2 0 2 1 1 5 3 2 1 2 1 4 2 1 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 2 1 2 1 2 1 1 1 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 2 1 2 1 2 2 1 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 3 2 1 1 1 2 2 0 1 0 0 0 0 1 0
3 1 2 0 2 2 2 5 1 1 1 1 2 1 2 7 0 1 0 0 0 1 1 12 1 0
3 2 2 0 2 2 2 5 1 2 1 2 1 1 0 1 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 1 2 1 2 1 7 1 0 0 0 0 1 1 12 1 0
3 2 2 5 2 2 2 5 1 2 1 1 1 2 0 1 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 2 1 3 1 2 1 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 2 1 3 1 7 1 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 1 1 3 1 4 2 0 1 0 0 0 1 1 1 0
3 2 2 0 2 2 2 5 1 2 1 2 1 2 1 0 0 0 0 0 1 0
3 1 2 0 2 2 2 5 1 1 1 1 1 1 2 1 2 1 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 1 1 1 2 1 2 0 1 0 0 0 0 1 0
3 1 2 0 2 2 2 5 1 1 2 1 2 1 3 1 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 1 1 2 1 2 1 2 1 1 0 0 0 0 1 0
Symptoms and signs Co-Morbid Conditions USG Ab CBC
3 2 2 0 2 2 2 5 1 1 1 1 2 2 0 1 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 2 1 1 1 1 2 1 0 0 0 0 0 1 0
3 2 2 5 2 2 2 5 1 2 1 1 1 2 1 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 1 1 1 1 1 1 1 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 2 1 2 1 7 0 1 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 1 1 1 1 2 1 0 0 0 0 0 1 0
2 2 2 5 2 2 2 5 2 2 1 2 1 3 2 0 1 0 2 0 0 1 0
3 2 2 0 2 2 2 5 1 2 1 2 1 2 7 1 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 2 1 1 1 1 2 0 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 2 1 1 1 1 2 0 1 0 0 0 0 1 0
1 1 2 0 2 2 2 5 1 1 1 2 1 2 1 1 2 0 1 0 1 0 1 2 1 0
3 2 2 0 2 2 2 5 1 1 1 1 2 1 7 1 1 0 1 0 1 1 12 1 0
3 2 2 0 2 2 2 5 2 1 2 1 2 1 2 0 1 0 2 0 1 1 1 0
1 1 2 0 2 2 2 5 1 1 1 1 2 1 1 2 0 1 0 1 0 0 1 0
3 2 2 5 2 2 2 5 1 2 1 3 1 1 2 1 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 2 1 1 1 2 0 1 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 2 1 3 1 1 1 0 1 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 1 2 1 1 2 0 1 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 1 1 2 1 1 1 7 1 0 0 0 0 1 1 1 0
3 2 2 0 2 2 2 5 1 1 1 2 1 2 1 1 1 0 0 0 1 0
3 2 2 0 2 2 2 5 1 1 1 1 1 1 2 1 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 2 1 1 1 2 0 1 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 1 1 3 1 1 7 1 0 0 0 0 1 1 1 0
3 2 2 12 2 2 2 5 1 1 1 1 2 1 1 1 0 1 0 1 0 0 1 0
3 2 2 0 2 2 2 5 1 1 1 1 2 1 1 2 1 0 0 1 0 0 1 0
3 2 2 0 2 2 2 5 2 1 1 1 3 1 1 7 1 1 0 2 0 1 1 12 1 0
3 2 2 0 2 2 2 5 1 1 2 1 1 1 1 2 1 0 0 0 0 0 1 0
3 2 2 5 2 2 2 5 1 1 1 3 1 1 2 1 0 0 0 0 0 1 0
1 2 2 0 2 2 2 5 1 1 1 1 1 2 1 2 2 1 0 0 1 0 0 1 0
1 2 2 0 2 2 2 5 1 1 2 1 2 1 1 2 1 0 0 1 0 0 1 0
3 2 2 5 2 2 2 5 1 1 1 1 1 1 2 1 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 1 1 1 1 1 2 0 1 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 1 1 1 1 2 1 1 2 1 0 0 1 0 0 1 0
3 2 2 0 2 2 2 5 1 2 1 2 1 1 1 1 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 1 1 1 1 1 2 1 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 1 1 1 2 1 1 1 0 1 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 2 1 2 1 1 7 1 0 0 0 0 1 1 1 0
3 2 2 0 2 2 2 5 1 2 1 1 1 3 1 0 0 0 0 0 1 0
3 2 2 5 2 2 2 5 1 2 1 2 1 2 1 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 1 2 1 2 1 2 1 0 0 1 0 0 1 0
3 2 2 0 2 2 2 5 1 2 1 2 1 2 1 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 1 1 1 1 1 7 0 1 0 0 0 1 1 1 0
3 2 2 0 2 2 2 5 1 2 1 1 1 1 2 0 1 0 0 0 0 1 0
3 2 2 5 2 2 2 2 1 2 1 2 1 1 2 1 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 1 1 1 1 1 2 1 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 2 1 1 1 1 2 1 0 0 0 0 0 1 0
2 2 2 5 2 2 2 5 2 2 1 1 1 1 2 1 0 0 2 0 0 1 0
3 2 2 0 2 2 2 5 1 2 1 1 1 2 1 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 2 1 1 1 1 2 1 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 2 1 2 1 2 1 0 0 0 0 0 1 0
3 2 2 5 2 2 2 5 1 1 1 1 1 2 1 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 2 1 2 1 2 1 0 0 0 0 0 1 0
3 2 2 5 2 2 2 5 1 2 1 3 1 2 1 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 1 1 1 3 1 7 0 1 0 0 0 1 1 1 0
3 2 2 12 2 2 2 5 1 2 1 3 1 2 0 1 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 1 1 3 1 1 2 1 0 0 0 0 1 1 1 0
3 2 2 5 2 2 2 5 1 2 1 2 1 3 1 2 1 0 0 0 0 1 1 1 123 1 0
3 2 2 0 2 2 2 5 1 1 1 2 1 7 1 0 0 0 0 1 1 1 0
3 2 2 5 2 2 2 5 1 2 1 2 1 2 1 0 0 0 0 1 1 12 1 0
3 2 2 12 2 2 2 5 1 1 1 2 1 2 0 1 0 0 0 1 1 1 0
3 2 2 0 2 2 2 5 1 1 1 2 2 7 1 0 0 0 0 1 1 1 0
3 1 2 0 2 2 2 5 1 5 1 1 2 1 2 1 0 0 0 0 1 1 12 1 0
3 2 2 0 2 2 2 5 1 1 1 3 1 3 1 0 0 0 0 0 1 0
3 2 2 12 2 2 2 5 6 2 1 2 1 2 1 0 0 0 0 1 1 1 0
3 2 2 12 2 2 2 5 1 2 1 2 1 2 1 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 2 1 3 1 7 1 0 0 0 0 1 1 12 1 0
3 2 2 0 2 2 2 5 1 2 1 2 1 1 0 1 0 0 0 0 1 0
3 2 2 5 2 2 2 5 1 1 1 2 1 2 1 0 0 0 0 0 1 0
3 2 2 12 2 2 2 5 1 2 1 2 1 3 1 2 0 1 0 0 0 1 1 1 0
2 2 2 5 2 2 2 5 1 2 2 1 2 1 2 1 0 0 0 0 1 1 1 123 1 0
3 2 2 0 2 2 2 5 1 1 1 2 1 7 1 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 1 1 3 1 4 1 1 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 1 1 3 1 7 0 1 0 0 0 0 1 0
3 2 2 5 2 2 2 5 1 1 1 3 1 7 1 0 0 0 0 1 1 1 0
3 2 1 12 2 2 2 5 1 1 1 1 1 3 1 1 2 1 0 0 0 2 1 1 12 1 1
3 2 2 0 2 2 2 5 1 1 1 3 1 7 0 1 0 0 0 1 1 1 0
3 2 2 0 2 2 2 5 1 1 1 2 1 3 1 0 0 0 0 0 1 0
2 2 2 0 2 2 2 5 1 2 2 2 1 7 1 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 1 1 3 1 7 0 1 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 1 1 3 1 1 1 0 0 0 0 1 1 1 0
2 2 2 0 2 2 2 5 1 1 2 1 2 1 7 1 0 0 0 0 1 1 1 0
3 2 2 0 2 2 2 5 1 1 1 2 1 1 1 2 1 7 1 0 0 0 0 1 1 1 0
3 2 2 0 2 2 2 5 1 1 1 3 1 7 1 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 1 1 1 1 2 1 7 0 1 0 0 0 1 1 1 0
2 1 2 0 2 2 2 5 2 1 2 1 2 1 7 1 0 0 0 0 0 1 0
3 2 2 5 2 2 2 5 1 1 1 2 1 2 1 0 0 0 0 0 1 0
3 2 2 12 2 2 2 5 1 2 2 1 2 1 1 2 0 1 1 0 0 1 1 1 0
3 2 2 0 2 2 2 5 1 2 1 3 1 7 0 1 0 0 0 1 1 1 0
3 2 2 12 2 2 2 5 1 2 1 3 1 2 1 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 2 1 2 1 2 1 7 0 1 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 1 2 3 1 7 0 1 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 2 1 3 1 7 1 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 2 1 3 1 7 0 1 0 0 0 1 1 1 0
3 2 2 5 2 2 2 5 1 2 1 3 1 2 1 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 2 1 2 1 7 0 1 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 2 1 3 1 7 1 0 0 0 0 1 1 1 0
3 2 2 0 2 2 2 5 1 2 1 2 1 1 1 7 0 1 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 1 1 3 1 7 1 0 0 0 0 1 1 1 0
3 2 2 0 2 2 2 5 1 2 1 1 2 1 7 1 0 0 0 0 1 1 1 0
3 2 2 12 2 2 2 5 1 1 2 1 3 1 1 4 0 1 0 0 0 1 1 1 0
2 1 2 0 2 2 2 5 2 1 1 1 3 1 7 1 0 0 0 0 1 1 1 0
2 2 2 0 2 2 2 5 1 2 2 1 2 1 7 1 0 0 0 0 1 1 12 1 0
3 2 2 0 2 2 2 5 1 1 1 1 2 1 7 1 0 0 0 0 1 1 1 0
3 2 2 0 2 2 2 5 1 2 1 1 1 3 1 7 0 1 0 0 0 1 1 1 0
3 1 2 0 2 2 2 5 1 1 2 2 1 3 1 7 0 1 0 0 0 1 1 12 1 0
3 2 2 0 2 2 2 5 1 2 1 2 2 1 1 7 0 1 0 0 0 1 2 1 0
3 2 2 0 2 2 2 5 1 1 2 2 1 1 1 7 0 1 0 0 0 0 1 0
3 2 2 0 2 1 2 5 1 2 2 1 1 7 0 1 1 0 0 0 1 0
3 2 2 12 2 2 2 5 1 2 2 1 1 2 0 1 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 1 2 2 1 1 7 0 1 0 0 0 1 2 1 0
3 2 2 0 2 2 2 5 1 2 2 1 1 7 1 0 0 0 0 1 1 1 0
3 2 2 0 2 2 2 5 1 2 2 1 1 1 1 1 1 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 2 2 1 1 1 7 1 0 0 0 0 0 1 0
2 2 2 0 2 1 2 5 2 7 2 2 1 1 1 7 1 0 0 0 0 1 1 1 0
3 2 2 0 2 2 2 5 1 2 2 1 1 1 1 3 0 1 0 0 0 1 1 1 0
3 2 2 0 2 2 2 5 1 2 2 1 1 1 7 1 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 2 2 1 1 5 7 1 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 1 2 2 1 1 7 1 0 0 0 0 1 1 1 0
3 2 2 0 2 2 1 5 1 2 2 1 2 1 7 0 1 0 0 0 1 1 1 0
3 2 2 0 2 2 2 5 1 1 2 2 1 1 1 7 1 0 0 1 0 0 1 0
3 2 2 0 2 2 2 5 1 1 2 2 1 1 7 1 0 0 0 0 1 1 1 0
2 2 2 0 2 2 2 5 1 1 2 2 2 1 1 7 0 1 0 0 0 0 1 0
3 2 2 0 2 1 2 5 9 2 2 1 1 1 0 1 0 0 0 1 1 1 123 1 0
3 1 2 0 2 2 2 5 1 1 2 2 1 1 7 1 0 0 0 0 1 1 1 0
3 2 2 0 2 2 2 5 1 1 2 2 1 1 7 0 1 0 0 0 1 1 1 0
2 1 2 0 2 2 2 5 1 1 2 2 1 1 5 7 1 0 0 0 0 1 1 1 0
3 2 2 0 2 2 1 5 1 1 2 2 1 1 2 5 1 0 0 3 0 0 1 0
3 1 2 0 2 2 2 5 1 2 2 1 1 2 7 1 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 2 2 1 1 2 7 1 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 2 2 1 1 2 1 1 1 0 0 0 1 1 1 0
3 1 2 0 2 2 2 5 1 1 2 2 1 1 2 1 0 1 0 0 0 1 1 1 0
1 1 2 0 2 2 2 5 1 1 2 2 1 1 2 7 1 0 0 0 0 0 1 0
1 2 2 0 2 2 2 5 1 1 2 2 1 1 2 1 1 0 0 0 0 1 1 1 0
2 1 2 0 2 2 2 5 1 2 1 2 2 1 1 2 1 1 0 0 0 0 1 1 1 0
3 2 2 0 2 2 2 5 1 2 2 1 1 2 7 1 0 0 0 0 1 1 1 0
3 2 2 0 2 2 2 5 1 2 2 1 1 4 1 7 0 1 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 2 2 1 1 7 1 0 0 0 0 0 1 0
3 1 1 0 2 2 2 5 1 2 2 1 1 1 1 0 1 0 0 3 1 1 1 0
3 1 2 0 2 2 2 5 1 1 2 2 1 1 1 7 1 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 2 2 2 1 1 7 0 1 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 2 2 1 1 7 0 1 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 2 2 1 1 4 6 1 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 2 2 1 1 7 0 1 0 0 3 0 1 0
3 2 2 0 2 2 2 5 1 2 2 1 2 3 1 7 0 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 2 2 1 1 7 1 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 2 2 1 1 7 1 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 2 2 1 1 7 1 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 2 2 1 1 7 0 1 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 2 2 1 1 7 1 0 0 0 0 1 1 1 0
3 2 2 0 2 2 2 5 1 2 2 1 1 7 0 1 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 2 2 1 1 1 0 1 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 2 2 1 1 7 0 1 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 2 2 1 1 7 0 1 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 2 2 1 1 1 0 1 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 1 2 2 1 1 7 1 1 0 0 0 1 1 1 0
3 2 2 0 2 2 2 5 1 2 2 1 1 7 1 0 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 2 2 1 1 2 1 1 0 0 0 0 0 1 0
3 1 2 0 2 2 2 5 1 1 2 2 2 1 1 2 7 1 0 0 0 0 1 1 1 0
3 2 2 0 2 2 2 5 1 2 2 1 1 2 7 1 1 0 0 0 0 1 0
3 2 2 0 2 2 2 5 1 2 2 1 1 2 1 0 1 0 0 0 0 1 0
3 2 2 1 2 2 2 5 1 1 1 2 1 7 0 1 0 0 0 0 1 0
3 2 2 1 2 2 2 5 4 1 1 2 1 7 1 0 0 0 0 0 1 0
3 2 2 1 2 2 2 5 1 1 2 1 1 7 0 1 0 0 0 0 1 0
3 2 2 1 2 2 2 5 1 2 1 1 1 4 7 1 0 0 0 0 0 1 0
3 1 2 1 2 2 2 5 1 2 1 3 1 1 1 0 0 0 0 1 1 1 0
3 2 2 1 2 2 2 5 1 1 1 2 1 7 1 1 0 0 0 0 1 0
3 2 2 1 2 2 2 5 1 2 1 1 1 7 0 1 0 0 0 0 1 0
3 2 2 1 2 2 2 5 1 1 1 1 1 7 1 1 1 0 0 0 1 0
3 2 2 1 2 2 2 5 1 1 1 1 1 7 1 0 0 0 0 0 1 0
3 2 2 1 2 2 2 5 1 1 1 2 1 2 1 0 0 0 0 0 1 0
3 2 2 1 2 2 2 5 1 2 1 3 1 7 0 1 0 0 0 0 1 0
3 2 2 1 2 2 2 5 1 1 2 2 1 2 1 7 0 1 0 0 0 1 1 1 0
2 2 2 1 2 2 2 5 1 1 2 2 1 2 1 1 2 0 1 0 0 0 1 1 1 0
3 2 2 1 2 2 2 5 1 2 1 3 1 2 1 0 0 0 0 0 1 0
2 2 2 1 2 2 2 5 1 2 2 1 1 7 0 1 0 0 0 1 1 1 0
3 2 2 1 2 2 2 5 1 2 2 1 1 1 1 0 1 0 0 0 1 1 1 0
3 2 2 1 2 2 2 4 1 2 2 1 1 1 7 1 0 0 0 0 0 1 0
3 2 2 1 2 2 2 5 1 2 2 1 1 7 1 0 0 0 0 0 1 0
3 1 2 1 2 2 2 5 1 1 2 2 1 1 2 7 0 1 0 0 0 1 1 1 0
3 2 2 1 2 2 2 5 1 2 2 1 1 3 1 0 1 0 0 0 0 1 0
3 2 2 1 2 2 2 5 1 2 2 1 2 2 4 1 0 0 0 0 0 1 0
3 2 2 1 2 2 2 5 1 2 2 1 1 7 1 0 0 0 0 0 1 0
3 1 2 1 2 2 2 5 1 1 2 2 1 1 7 1 0 0 0 0 0 1 0
3 1 2 1 2 2 2 5 1 2 2 1 2 2 7 1 0 0 0 0 0 1 0
3 2 2 1 2 2 2 5 1 2 2 1 1 2 7 0 1 0 0 0 0 1 0
3 2 2 2 2 2 2 5 1 1 1 3 1 7 0 1 0 0 0 0 1 0
3 2 2 3 2 2 2 5 1 1 1 3 1 7 1 1 0 0 0 1 2 1 0
3 2 2 3 2 2 2 5 1 1 1 1 1 7 0 1 0 0 0 0 1 0
3 2 2 3 2 2 2 5 1 2 1 2 1 7 1 0 0 0 0 0 1 0
3 2 2 3 2 2 2 5 1 1 1 2 1 7 0 1 0 0 0 0 1 0
3 2 2 3 2 2 2 5 1 1 1 1 1 7 0 1 0 0 0 0 1 0
3 2 2 3 2 2 2 5 1 2 1 1 1 7 1 0 0 0 0 0 1 0
3 2 2 3 2 2 2 5 1 1 1 3 1 7 1 0 0 0 0 1 1 1 0
3 2 2 3 2 2 2 5 1 1 1 1 1 7 1 0 0 0 0 0 1 0
3 2 2 3 2 2 2 5 1 1 1 3 1 1 7 1 0 0 0 0 1 2 1 0
3 2 2 3 2 2 2 5 1 1 1 2 2 1 1 7 0 1 0 1 0 0 1 0
3 2 1 3 2 2 2 5 1 2 2 1 1 2 2 1 1 0 0 0 1 1 12 1 1
3 2 2 3 2 2 2 5 1 2 2 1 1 7 1 1 0 0 0 0 1 0
3 2 2 3 2 2 2 5 1 2 2 1 1 7 1 0 0 0 0 0 1 0
3 2 2 3 2 2 2 3 1 2 2 1 1 7 1 0 0 0 0 0 1 0
3 2 2 3 2 2 2 5 1 2 2 1 1 2 1 1 1 0 0 0 0 1 0
3 2 2 3 2 2 2 5 1 2 2 1 1 7 1 0 0 0 0 0 1 0
3 2 1 4 2 2 2 5 2 2 1 2 1 2 2 1 0 0 0 1 1 1 1 0
3 2 2 5 2 2 2 5 1 1 1 3 1 7 1 0 0 0 0 0 1 0
3 2 2 6 2 2 2 5 1 1 1 2 1 3 1 1 1 1 1 1 0 0 0 1 1 1 0
3 2 2 7 2 2 2 5 1 1 1 3 1 2 1 7 0 1 0 0 0 1 1 1 0
3 2 2 7 2 2 2 5 2 2 1 3 1 7 1 0 0 0 0 1 1 1 0
3 2 2 7 2 2 2 5 1 1 1 1 2 1 7 0 1 0 0 0 1 1 1 0
3 2 2 7 2 2 2 5 1 2 2 1 1 7 0 1 0 0 0 0 1 0
3 2 2 8 2 2 2 5 1 2 2 1 1 1 7 0 1 0 0 0 1 2 1 0
2 2 2 9 2 2 2 5 1 2 1 8 2 2 1 1 2 1 0 0 0 0 1 1 1 0
3 2 2 10 2 2 2 5 2 2 2 1 1 7 1 0 0 2 0 0 1 0
3 2 2 11 2 2 2 5 1 1 2 2 1 1 7 1 0 0 0 0 1 1 1 0
3 2 2 12 2 2 2 5 1 1 2 2 1 3 1 1 0 1 0 0 0 1 1 1 0
